sentence,entity_1,entity_2,relation_label,entity_1_original,entity_2_original,input_text
"Exploring emotion recognition in patients with mild cognitive impairment and 
Alzheimer's dementia undergoing a rehabilitation program emotion recognition in 
patients with dementia.",Alzheimer's disease,dementia,associated_with,Alzheimer's dementia,dementia,"Exploring emotion recognition in patients with mild cognitive impairment and 
[E1] Alzheimer's [E2] dementia [/E2] [/E1] undergoing a rehabilitation program emotion recognition in 
patients with dementia."
"Exploring emotion recognition in patients with mild cognitive impairment and 
Alzheimer's dementia undergoing a rehabilitation program emotion recognition in 
patients with dementia.",Alzheimer's disease,cognitive impairment,ambiguous,Alzheimer's dementia,cognitive impairment,"Exploring emotion recognition in patients with mild [E2] cognitive impairment [/E2] and 
[E1] Alzheimer's dementia [/E1] undergoing a rehabilitation program emotion recognition in 
patients with dementia."
"AIM: This study aimed to explore differences in the emotions of patients with 
mild cognitive impairment (MCI) and Alzheimer's dementia (AD) in group 
rehabilitation using facial analysis.",Alzheimer's disease,mci,ambiguous,Alzheimer's dementia,MCI,"AIM: This study aimed to explore differences in the emotions of patients with 
mild cognitive impairment ([E2] MCI [/E2]) and [E1] Alzheimer's dementia [/E1] (AD) in group 
rehabilitation using facial analysis."
"AIM: This study aimed to explore differences in the emotions of patients with 
mild cognitive impairment (MCI) and Alzheimer's dementia (AD) in group 
rehabilitation using facial analysis.",Alzheimer's disease,cognitive impairment,ambiguous,Alzheimer's dementia,cognitive impairment,"AIM: This study aimed to explore differences in the emotions of patients with 
mild [E2] cognitive impairment [/E2] (MCI) and [E1] Alzheimer's dementia [/E1] (AD) in group 
rehabilitation using facial analysis."
"AIM: This study aimed to explore differences in the emotions of patients with 
mild cognitive impairment (MCI) and Alzheimer's dementia (AD) in group 
rehabilitation using facial analysis.",Alzheimer's disease,ad,equivalent,Alzheimer's dementia,AD,"AIM: This study aimed to explore differences in the emotions of patients with 
mild cognitive impairment (MCI) and [E1] Alzheimer's dementia [/E1] ([E2] AD [/E2]) in group 
rehabilitation using facial analysis."
"Reliability and modeling of digital histological measurements in Alzheimer's 
disease neuropathologic change and Lewy body disease.",Alzheimer's disease,lewy body disease,ambiguous,"Alzheimer's 
disease neuropathologic change",Lewy body disease,"Reliability and modeling of digital histological measurements in [E1] Alzheimer's 
disease neuropathologic change [/E1] and [E2] Lewy body disease [/E2]."
"We calculated regional percentage areas occupied by 
phosphorylated tau (p-Tau, AT8), amyloid-ÃÂ² (AÃÂ², NAB228), and phosphorylated 
ÃÂ±-synuclein (p-ÃÂ±Syn, 81A) pathology in 24 autopsied cases with varying degrees 
of Alzheimer disease neuropathological change and Lewy body disease (LBD) using 
manual and automated immunostaining methods to investigate variability across 
protocols.",Alzheimer's disease,lewy body disease,ambiguous,Alzheimer disease,Lewy body disease,"We calculated regional percentage areas occupied by 
phosphorylated tau (p-Tau, AT8), amyloid-ÃÂ² (AÃÂ², NAB228), and phosphorylated 
ÃÂ±-synuclein (p-ÃÂ±Syn, 81A) pathology in 24 autopsied cases with varying degrees 
of [E1] Alzheimer disease [/E1] neuropathological change and [E2] Lewy body disease [/E2] (LBD) using 
manual and automated immunostaining methods to investigate variability across 
protocols."
"Author information:
(1)Mitchell Center for Alzheimer's Disease and Related Brain Disorders, 
Department of Neurology, University of Texas McGovern Medical School at Houston, 
Houston, TX, USA.
(2)UTHealth Houston Graduate School of Biomedical Sciences, The University of 
Texas MD Anderson Cancer Center, 6767 Bertner Avenue, Houston, TX 77030, USA.",Alzheimer's disease,cancer,unrelated,Alzheimer's Disease and Related Brain Disorders,Cancer,"Author information:
(1)Mitchell Center for [E1] Alzheimer's Disease and Related Brain Disorders [/E1], 
Department of Neurology, University of Texas McGovern Medical School at Houston, 
Houston, TX, USA.
(2)UTHealth Houston Graduate School of Biomedical Sciences, The University of 
Texas MD Anderson [E2] Cancer [/E2] Center, 6767 Bertner Avenue, Houston, TX 77030, USA."
"MethodTen family carers of people with dementia (4 
frontotemporal dementia, 3 Alzheimer's disease, 3 Lewy body dementia, 1 Vascular 
dementia) in Australia participated in focus groups and interviews.",Alzheimer's disease,dementia,ambiguous,Alzheimer's disease,dementia,"MethodTen family carers of people with [E2] dementia [/E2] (4 
frontotemporal dementia, 3 [E1] Alzheimer's disease [/E1], 3 Lewy body dementia, 1 Vascular 
dementia) in Australia participated in focus groups and interviews."
"The global rise in both metabolic syndrome (MetS) and neurodegenerative diseases 
(NDs), particularly dementia and Alzheimer's disease (AD) poses a growing health 
and socioeconomic burden.",Alzheimer's disease,neurodegenerative diseases,associated_with,Alzheimer's disease,neurodegenerative diseases,"The global rise in both metabolic syndrome (MetS) and [E2] neurodegenerative diseases [/E2] 
(NDs), particularly dementia and [E1] Alzheimer's disease [/E1] (AD) poses a growing health 
and socioeconomic burden."
"The global rise in both metabolic syndrome (MetS) and neurodegenerative diseases 
(NDs), particularly dementia and Alzheimer's disease (AD) poses a growing health 
and socioeconomic burden.",Alzheimer's disease,mets,ambiguous,Alzheimer's disease,MetS,"The global rise in both metabolic syndrome ([E2] MetS [/E2]) and neurodegenerative diseases 
(NDs), particularly dementia and [E1] Alzheimer's disease [/E1] (AD) poses a growing health 
and socioeconomic burden."
"The global rise in both metabolic syndrome (MetS) and neurodegenerative diseases 
(NDs), particularly dementia and Alzheimer's disease (AD) poses a growing health 
and socioeconomic burden.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"The global rise in both metabolic syndrome (MetS) and neurodegenerative diseases 
(NDs), particularly dementia and [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) poses a growing health 
and socioeconomic burden."
"The global rise in both metabolic syndrome (MetS) and neurodegenerative diseases 
(NDs), particularly dementia and Alzheimer's disease (AD) poses a growing health 
and socioeconomic burden.",Alzheimer's disease,metabolic syndrome,ambiguous,Alzheimer's disease,metabolic syndrome,"The global rise in both [E2] metabolic syndrome [/E2] (MetS) and neurodegenerative diseases 
(NDs), particularly dementia and [E1] Alzheimer's disease [/E1] (AD) poses a growing health 
and socioeconomic burden."
"The global rise in both metabolic syndrome (MetS) and neurodegenerative diseases 
(NDs), particularly dementia and Alzheimer's disease (AD) poses a growing health 
and socioeconomic burden.",Alzheimer's disease,dementia,ambiguous,Alzheimer's disease,dementia,"The global rise in both metabolic syndrome (MetS) and neurodegenerative diseases 
(NDs), particularly [E2] dementia [/E2] and [E1] Alzheimer's disease [/E1] (AD) poses a growing health 
and socioeconomic burden."
"Normal cerebral oxygen consumption and lactate levels in patients with 
Alzheimer's disease and Lewy body dementia.",Alzheimer's disease,lewy body dementia,ambiguous,Alzheimer's disease,Lewy body dementia,"Normal cerebral oxygen consumption and lactate levels in patients with 
[E1] Alzheimer's disease [/E1] and [E2] Lewy body dementia [/E2]."
"In the current exploratory study, we investigated brain 
lactate, global and regional CBF, and global cerebral metabolic rate of oxygen 
(CMRO2) in patients with Alzheimer's disease (AD) and dementia with Lewy bodies 
(DLBs).",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"In the current exploratory study, we investigated brain 
lactate, global and regional CBF, and global cerebral metabolic rate of oxygen 
(CMRO2) in patients with [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) and dementia with Lewy bodies 
(DLBs)."
"In the current exploratory study, we investigated brain 
lactate, global and regional CBF, and global cerebral metabolic rate of oxygen 
(CMRO2) in patients with Alzheimer's disease (AD) and dementia with Lewy bodies 
(DLBs).",Alzheimer's disease,lewy,associated_with,Alzheimer's disease,Lewy,"In the current exploratory study, we investigated brain 
lactate, global and regional CBF, and global cerebral metabolic rate of oxygen 
(CMRO2) in patients with [E1] Alzheimer's disease [/E1] (AD) and dementia with [E2] Lewy [/E2] bodies 
(DLBs)."
"In the current exploratory study, we investigated brain 
lactate, global and regional CBF, and global cerebral metabolic rate of oxygen 
(CMRO2) in patients with Alzheimer's disease (AD) and dementia with Lewy bodies 
(DLBs).",Alzheimer's disease,dlbs,associated_with,Alzheimer's disease,DLBs,"In the current exploratory study, we investigated brain 
lactate, global and regional CBF, and global cerebral metabolic rate of oxygen 
(CMRO2) in patients with [E1] Alzheimer's disease [/E1] (AD) and dementia with Lewy bodies 
([E2] DLBs [/E2])."
"In the current exploratory study, we investigated brain 
lactate, global and regional CBF, and global cerebral metabolic rate of oxygen 
(CMRO2) in patients with Alzheimer's disease (AD) and dementia with Lewy bodies 
(DLBs).",Alzheimer's disease,dementia,ambiguous,Alzheimer's disease,dementia,"In the current exploratory study, we investigated brain 
lactate, global and regional CBF, and global cerebral metabolic rate of oxygen 
(CMRO2) in patients with [E1] Alzheimer's disease [/E1] (AD) and [E2] dementia [/E2] with Lewy bodies 
(DLBs)."
"Alzheimer's disease (AD) is a progressive neurodegenerative disorder 
characterized by neuroinflammation and cognitive impairments.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"[E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) is a progressive neurodegenerative disorder 
characterized by neuroinflammation and cognitive impairments."
"Alzheimer's disease (AD) is a progressive neurodegenerative disorder 
characterized by neuroinflammation and cognitive impairments.",Alzheimer's disease,neuroinflammation,associated_with,Alzheimer's disease,neuroinflammation,"[E1] Alzheimer's disease [/E1] (AD) is a progressive neurodegenerative disorder 
characterized by [E2] neuroinflammation [/E2] and cognitive impairments."
"Alzheimer's disease (AD) is a progressive neurodegenerative disorder 
characterized by neuroinflammation and cognitive impairments.",Alzheimer's disease,neurodegenerative disorder,associated_with,Alzheimer's disease,neurodegenerative disorder,"[E1] Alzheimer's disease [/E1] (AD) is a progressive [E2] neurodegenerative disorder [/E2] 
characterized by neuroinflammation and cognitive impairments."
"Alzheimer's disease (AD) is a progressive neurodegenerative disorder 
characterized by neuroinflammation and cognitive impairments.",Alzheimer's disease,cognitive impairments,associated_with,Alzheimer's disease,cognitive impairments,"[E1] Alzheimer's disease [/E1] (AD) is a progressive neurodegenerative disorder 
characterized by neuroinflammation and [E2] cognitive impairments [/E2]."
"This study examines the association between HCoVs and 
neurodegenerative diseases like Alzheimer disease, Parkinson disease, Lewy body 
dementia, amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease.",Alzheimer's disease,neurodegenerative diseases,associated_with,Alzheimer disease,neurodegenerative diseases,"This study examines the association between HCoVs and 
[E2] neurodegenerative diseases [/E2] like [E1] Alzheimer disease [/E1], Parkinson disease, Lewy body 
dementia, amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease."
"This study examines the association between HCoVs and 
neurodegenerative diseases like Alzheimer disease, Parkinson disease, Lewy body 
dementia, amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease.",Alzheimer's disease,amyotrophic lateral sclerosis,ambiguous,Alzheimer disease,amyotrophic lateral sclerosis,"This study examines the association between HCoVs and 
neurodegenerative diseases like [E1] Alzheimer disease [/E1], Parkinson disease, Lewy body 
dementia, [E2] amyotrophic lateral sclerosis [/E2], and Creutzfeldt-Jakob disease."
"This study examines the association between HCoVs and 
neurodegenerative diseases like Alzheimer disease, Parkinson disease, Lewy body 
dementia, amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease.",Alzheimer's disease,parkinson disease,ambiguous,Alzheimer disease,Parkinson disease,"This study examines the association between HCoVs and 
neurodegenerative diseases like [E1] Alzheimer disease [/E1], [E2] Parkinson disease [/E2], Lewy body 
dementia, amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease."
"This study examines the association between HCoVs and 
neurodegenerative diseases like Alzheimer disease, Parkinson disease, Lewy body 
dementia, amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease.",Alzheimer's disease,creutzfeldt-jakob disease,ambiguous,Alzheimer disease,Creutzfeldt-Jakob disease,"This study examines the association between HCoVs and 
neurodegenerative diseases like [E1] Alzheimer disease [/E1], Parkinson disease, Lewy body 
dementia, amyotrophic lateral sclerosis, and [E2] Creutzfeldt-Jakob disease [/E2]."
"This study examines the association between HCoVs and 
neurodegenerative diseases like Alzheimer disease, Parkinson disease, Lewy body 
dementia, amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease.",Alzheimer's disease,lewy,ambiguous,Alzheimer disease,Lewy,"This study examines the association between HCoVs and 
neurodegenerative diseases like [E1] Alzheimer disease [/E1], Parkinson disease, [E2] Lewy [/E2] body 
dementia, amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease."
"This study examines the association between HCoVs and 
neurodegenerative diseases like Alzheimer disease, Parkinson disease, Lewy body 
dementia, amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease.",Alzheimer's disease,dementia,ambiguous,Alzheimer disease,dementia,"This study examines the association between HCoVs and 
neurodegenerative diseases like [E1] Alzheimer disease [/E1], Parkinson disease, Lewy body 
[E2] dementia [/E2], amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease."
"Little is known about the extent to which patient self-perception of 
care experience is associated with costs, especially for people with Alzheimer 
disease and related dementias (ADRD).",Alzheimer's disease,dementias,ambiguous,"Alzheimer 
disease",dementias,"Little is known about the extent to which patient self-perception of 
care experience is associated with costs, especially for people with [E1] Alzheimer 
disease [/E1] and related [E2] dementias [/E2] (ADRD)."
"Little is known about the extent to which patient self-perception of 
care experience is associated with costs, especially for people with Alzheimer 
disease and related dementias (ADRD).",Alzheimer's disease,adrd,ambiguous,"Alzheimer 
disease",ADRD,"Little is known about the extent to which patient self-perception of 
care experience is associated with costs, especially for people with [E1] Alzheimer 
disease [/E1] and related dementias ([E2] ADRD [/E2])."
"(14)Shiley-Marcos Alzheimer's Disease Research Center, University of California 
San Diego, La Jolla, California, USA.
(15)Department of Neurobiology and Behavior; Institute for Memory Impairments 
and Neurological Disorders, University of California, Irvine, California, USA.",Alzheimer's disease,memory impairments,ambiguous,"Alzheimer's Disease Research Center, University of California 
San Diego, La Jolla",Memory Impairments,"(14)Shiley-Marcos [E1] Alzheimer's Disease Research Center, University of California 
San Diego, La Jolla [/E1], California, USA.
(15)Department of Neurobiology and Behavior; Institute for [E2] Memory Impairments [/E2] 
and Neurological Disorders, University of California, Irvine, California, USA."
"Adult child caregivers of older adults living with Alzheimer's 
disease and related dementias are at risk of burnout due to competing caregiving 
demands from multiple generations.",Alzheimer's disease,dementias,associated_with,"Alzheimer's 
disease",dementias,"Adult child caregivers of older adults living with [E1] Alzheimer's 
disease [/E1] and related [E2] dementias [/E2] are at risk of burnout due to competing caregiving 
demands from multiple generations."
"This study investigates whether midlife cortisol levels predict 
Alzheimer's disease (AD) biomarker burden 15 years later, with particular 
attention to sex differences and menopausal status.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"This study investigates whether midlife cortisol levels predict 
[E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) biomarker burden 15 years later, with particular 
attention to sex differences and menopausal status."
"Extracellular ÃÂ²-amyloid protein (AÃÂ²) plaques are prominent pathological feature 
of Alzheimer's disease (AD).",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"Extracellular ÃÂ²-amyloid protein (AÃÂ²) plaques are prominent pathological feature 
of [E1] Alzheimer's disease [/E1] ([E2] AD [/E2])."
"Cognitive 
function was measured using the Consortium to Establish a Registry for 
Alzheimer's Disease (CERAD) test, Digit Symbol Substitution Test (DSST), and 
Animal Fluency Test, while depression was assessed through the Patient Health 
Questionnaire-9 (PHQ-9).",Alzheimer's disease,depression,ambiguous,Alzheimer's Disease,depression,"Cognitive 
function was measured using the Consortium to Establish a Registry for 
[E1] Alzheimer's Disease [/E1] (CERAD) test, Digit Symbol Substitution Test (DSST), and 
Animal Fluency Test, while [E2] depression [/E2] was assessed through the Patient Health 
Questionnaire-9 (PHQ-9)."
"Cognitive 
function was measured using the Consortium to Establish a Registry for 
Alzheimer's Disease (CERAD) test, Digit Symbol Substitution Test (DSST), and 
Animal Fluency Test, while depression was assessed through the Patient Health 
Questionnaire-9 (PHQ-9).",Alzheimer's disease,cerad,unrelated,Alzheimer's Disease,CERAD,"Cognitive 
function was measured using the Consortium to Establish a Registry for 
[E1] Alzheimer's Disease [/E1] ([E2] CERAD [/E2]) test, Digit Symbol Substitution Test (DSST), and 
Animal Fluency Test, while depression was assessed through the Patient Health 
Questionnaire-9 (PHQ-9)."
"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
depression, anxiety, bipolar disorder, and autism spectrum disorder, and ND, 
such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS).",Alzheimer's disease,depression,ambiguous,Alzheimer's disease,depression,"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
[E2] depression [/E2], anxiety, bipolar disorder, and autism spectrum disorder, and ND, 
such as [E1] Alzheimer's disease [/E1] (AD), Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS)."
"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
depression, anxiety, bipolar disorder, and autism spectrum disorder, and ND, 
such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS).",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
depression, anxiety, bipolar disorder, and autism spectrum disorder, and ND, 
such as [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]), Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS)."
"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
depression, anxiety, bipolar disorder, and autism spectrum disorder, and ND, 
such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS).",Alzheimer's disease,pd,ambiguous,Alzheimer's disease,PD,"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
depression, anxiety, bipolar disorder, and autism spectrum disorder, and ND, 
such as [E1] Alzheimer's disease [/E1] (AD), Parkinson's disease ([E2] PD [/E2]), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS)."
"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
depression, anxiety, bipolar disorder, and autism spectrum disorder, and ND, 
such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS).",Alzheimer's disease,anxiety,ambiguous,Alzheimer's disease,anxiety,"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
depression, [E2] anxiety [/E2], bipolar disorder, and autism spectrum disorder, and ND, 
such as [E1] Alzheimer's disease [/E1] (AD), Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS)."
"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
depression, anxiety, bipolar disorder, and autism spectrum disorder, and ND, 
such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS).",Alzheimer's disease,schizophrenia,ambiguous,Alzheimer's disease,schizophrenia,"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as [E2] schizophrenia [/E2], 
depression, anxiety, bipolar disorder, and autism spectrum disorder, and ND, 
such as [E1] Alzheimer's disease [/E1] (AD), Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS)."
"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
depression, anxiety, bipolar disorder, and autism spectrum disorder, and ND, 
such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS).",Alzheimer's disease,autism spectrum disorder,ambiguous,Alzheimer's disease,autism spectrum disorder,"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
depression, anxiety, bipolar disorder, and [E2] autism spectrum disorder [/E2], and ND, 
such as [E1] Alzheimer's disease [/E1] (AD), Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS)."
"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
depression, anxiety, bipolar disorder, and autism spectrum disorder, and ND, 
such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS).",Alzheimer's disease,bipolar disorder,ambiguous,Alzheimer's disease,bipolar disorder,"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
depression, anxiety, [E2] bipolar disorder [/E2], and autism spectrum disorder, and ND, 
such as [E1] Alzheimer's disease [/E1] (AD), Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS)."
"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
depression, anxiety, bipolar disorder, and autism spectrum disorder, and ND, 
such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS).",Alzheimer's disease,parkinson's disease,ambiguous,Alzheimer's disease,Parkinson's disease,"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
depression, anxiety, bipolar disorder, and autism spectrum disorder, and ND, 
such as [E1] Alzheimer's disease [/E1] (AD), [E2] Parkinson's disease [/E2] (PD), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS)."
"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
depression, anxiety, bipolar disorder, and autism spectrum disorder, and ND, 
such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis (ALS), and Multiple Sclerosis (MS).",Alzheimer's disease,als,ambiguous,Alzheimer's disease,ALS,"Furthermore, this review covers the encouraging 
results of supplementing sulfur-rich diets in many animal models and clinical 
investigations, along with their molecular targets in MD, such as schizophrenia, 
depression, anxiety, bipolar disorder, and autism spectrum disorder, and ND, 
such as [E1] Alzheimer's disease [/E1] (AD), Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis ([E2] ALS [/E2]), and Multiple Sclerosis (MS)."
"Cognitive function was assessed using the 
Consortium to Establish a Registry for Alzheimer's disease (CERAD), the Animal 
Fluency Test (AFT), and the Digital Symbol Substitution Test (DSST).",Alzheimer's disease,cerad,unrelated,Alzheimer's disease,CERAD,"Cognitive function was assessed using the 
Consortium to Establish a Registry for [E1] Alzheimer's disease [/E1] ([E2] CERAD [/E2]), the Animal 
Fluency Test (AFT), and the Digital Symbol Substitution Test (DSST)."
"(#)Contributed equally

Alzheimer's disease (AD) significantly reduces the quality of life of patients 
and exacerbates the burden on their families and society.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"(#)Contributed equally

[E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) significantly reduces the quality of life of patients 
and exacerbates the burden on their families and society."
"Danggui Shaoyao San ameliorates Alzheimer's disease by regulating lipid 
metabolism and inhibiting neuronal ferroptosis through the AMPK/Sp1/ACSL4 
signaling pathway.",Alzheimer's disease,neuronal ferroptosis,associated_with,Alzheimer's disease,neuronal ferroptosis,"Danggui Shaoyao San ameliorates [E1] Alzheimer's disease [/E1] by regulating lipid 
metabolism and inhibiting [E2] neuronal ferroptosis [/E2] through the AMPK/Sp1/ACSL4 
signaling pathway."
"Alzheimer's disease (AD) is a neurodegenerative disorder 
characterized by cognitive decline; recent studies suggest that neuronal 
ferroptosis plays a key role in its pathogenesis.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"[E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) is a neurodegenerative disorder 
characterized by cognitive decline; recent studies suggest that neuronal 
ferroptosis plays a key role in its pathogenesis."
"Alzheimer's disease (AD) is a neurodegenerative disorder 
characterized by cognitive decline; recent studies suggest that neuronal 
ferroptosis plays a key role in its pathogenesis.",Alzheimer's disease,neurodegenerative disorder,equivalent,Alzheimer's disease,neurodegenerative disorder,"[E1] Alzheimer's disease [/E1] (AD) is a [E2] neurodegenerative disorder [/E2] 
characterized by cognitive decline; recent studies suggest that neuronal 
ferroptosis plays a key role in its pathogenesis."
"Alzheimer's disease (AD) is a neurodegenerative disorder 
characterized by cognitive decline; recent studies suggest that neuronal 
ferroptosis plays a key role in its pathogenesis.",Alzheimer's disease,cognitive decline,associated_with,Alzheimer's disease,cognitive decline,"[E1] Alzheimer's disease [/E1] (AD) is a neurodegenerative disorder 
characterized by [E2] cognitive decline [/E2]; recent studies suggest that neuronal 
ferroptosis plays a key role in its pathogenesis."
"Diagnostic performance of Alzheimer's disease blood biomarkers in a Brazilian 
cohort.

Borelli WV, Ferreira PCL, Brum WS, Ferrari-Souza JP, Carello-Collar G, Holz M, 
Tizeli V, Strelow MZ, Formoso C, Fagundes Chaves ML, Rocha A, Aguzzoli CS, 
Rohden F, Souza DG, Schumacher Schuh AF, Povala G, Bellaver B, Rosa-Neto P, 
Castilhos RM, Pascoal TA, Zimmer ER.",Alzheimer's disease,ferrari-souza jp,unrelated,Alzheimer's disease blood biomarkers,Ferrari-Souza JP,"Diagnostic performance of [E1] Alzheimer's disease blood biomarkers [/E1] in a Brazilian 
cohort.

Borelli WV, Ferreira PCL, Brum WS, [E2] Ferrari-Souza JP [/E2], Carello-Collar G, Holz M, 
Tizeli V, Strelow MZ, Formoso C, Fagundes Chaves ML, Rocha A, Aguzzoli CS, 
Rohden F, Souza DG, Schumacher Schuh AF, Povala G, Bellaver B, Rosa-Neto P, 
Castilhos RM, Pascoal TA, Zimmer ER."
"Blood-based biomarkers (BBMs) have emerged as promising tools to enhance 
Alzheimer's disease (AD) diagnosis.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"Blood-based biomarkers (BBMs) have emerged as promising tools to enhance 
[E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) diagnosis."
"Utilizing data from the GBD Study 2021 on the incidence and 
disability-adjusted life-years (DALYs) of Alzheimer's disease (AD) and other 
dementias, Parkinson's disease, multiple sclerosis, and idiopathic epilepsy in 
women from 1990 to 2021.",Alzheimer's disease,dementias,ambiguous,Alzheimer's disease,dementias,"Utilizing data from the GBD Study 2021 on the incidence and 
disability-adjusted life-years (DALYs) of [E1] Alzheimer's disease [/E1] (AD) and other 
[E2] dementias [/E2], Parkinson's disease, multiple sclerosis, and idiopathic epilepsy in 
women from 1990 to 2021."
"Utilizing data from the GBD Study 2021 on the incidence and 
disability-adjusted life-years (DALYs) of Alzheimer's disease (AD) and other 
dementias, Parkinson's disease, multiple sclerosis, and idiopathic epilepsy in 
women from 1990 to 2021.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"Utilizing data from the GBD Study 2021 on the incidence and 
disability-adjusted life-years (DALYs) of [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) and other 
dementias, Parkinson's disease, multiple sclerosis, and idiopathic epilepsy in 
women from 1990 to 2021."
"Utilizing data from the GBD Study 2021 on the incidence and 
disability-adjusted life-years (DALYs) of Alzheimer's disease (AD) and other 
dementias, Parkinson's disease, multiple sclerosis, and idiopathic epilepsy in 
women from 1990 to 2021.",Alzheimer's disease,idiopathic epilepsy,ambiguous,Alzheimer's disease,idiopathic epilepsy,"Utilizing data from the GBD Study 2021 on the incidence and 
disability-adjusted life-years (DALYs) of [E1] Alzheimer's disease [/E1] (AD) and other 
dementias, Parkinson's disease, multiple sclerosis, and [E2] idiopathic epilepsy [/E2] in 
women from 1990 to 2021."
"Utilizing data from the GBD Study 2021 on the incidence and 
disability-adjusted life-years (DALYs) of Alzheimer's disease (AD) and other 
dementias, Parkinson's disease, multiple sclerosis, and idiopathic epilepsy in 
women from 1990 to 2021.",Alzheimer's disease,parkinson's disease,ambiguous,Alzheimer's disease,Parkinson's disease,"Utilizing data from the GBD Study 2021 on the incidence and 
disability-adjusted life-years (DALYs) of [E1] Alzheimer's disease [/E1] (AD) and other 
dementias, [E2] Parkinson's disease [/E2], multiple sclerosis, and idiopathic epilepsy in 
women from 1990 to 2021."
"Utilizing data from the GBD Study 2021 on the incidence and 
disability-adjusted life-years (DALYs) of Alzheimer's disease (AD) and other 
dementias, Parkinson's disease, multiple sclerosis, and idiopathic epilepsy in 
women from 1990 to 2021.",Alzheimer's disease,multiple sclerosis,ambiguous,Alzheimer's disease,multiple sclerosis,"Utilizing data from the GBD Study 2021 on the incidence and 
disability-adjusted life-years (DALYs) of [E1] Alzheimer's disease [/E1] (AD) and other 
dementias, Parkinson's disease, [E2] multiple sclerosis [/E2], and idiopathic epilepsy in 
women from 1990 to 2021."
"We conducted a cross-sectional assessment of the effect of EQ and YoE 
on brain health in 7533 subjects from 20 countries, including healthy controls 
(HCs), Alzheimer's disease (AD), and frontotemporal lobar degeneration (FTLD).",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"We conducted a cross-sectional assessment of the effect of EQ and YoE 
on brain health in 7533 subjects from 20 countries, including healthy controls 
(HCs), [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]), and frontotemporal lobar degeneration (FTLD)."
"We conducted a cross-sectional assessment of the effect of EQ and YoE 
on brain health in 7533 subjects from 20 countries, including healthy controls 
(HCs), Alzheimer's disease (AD), and frontotemporal lobar degeneration (FTLD).",Alzheimer's disease,frontotemporal lobar degeneration,ambiguous,Alzheimer's disease,frontotemporal lobar degeneration,"We conducted a cross-sectional assessment of the effect of EQ and YoE 
on brain health in 7533 subjects from 20 countries, including healthy controls 
(HCs), [E1] Alzheimer's disease [/E1] (AD), and [E2] frontotemporal lobar degeneration [/E2] (FTLD)."
"We conducted a cross-sectional assessment of the effect of EQ and YoE 
on brain health in 7533 subjects from 20 countries, including healthy controls 
(HCs), Alzheimer's disease (AD), and frontotemporal lobar degeneration (FTLD).",Alzheimer's disease,ftld,ambiguous,Alzheimer's disease,FTLD,"We conducted a cross-sectional assessment of the effect of EQ and YoE 
on brain health in 7533 subjects from 20 countries, including healthy controls 
(HCs), [E1] Alzheimer's disease [/E1] (AD), and frontotemporal lobar degeneration ([E2] FTLD [/E2])."
"It is a neurodegenerative illness-and the 
second most common type of dementia after Alzheimer's disease-that causes memory 
loss and severe problems in carrying out daily activities.",Alzheimer's disease,dementia,associated_with,Alzheimer's disease-that,dementia,"It is a neurodegenerative illness-and the 
second most common type of [E2] dementia [/E2] after [E1] Alzheimer's disease-that [/E1] causes memory 
loss and severe problems in carrying out daily activities."
"It is a neurodegenerative illness-and the 
second most common type of dementia after Alzheimer's disease-that causes memory 
loss and severe problems in carrying out daily activities.",Alzheimer's disease,neurodegenerative illness-and,unrelated,Alzheimer's disease-that,neurodegenerative illness-and,"It is a [E2] neurodegenerative illness-and [/E2] the 
second most common type of dementia after [E1] Alzheimer's disease-that [/E1] causes memory 
loss and severe problems in carrying out daily activities."
"It is a neurodegenerative illness-and the 
second most common type of dementia after Alzheimer's disease-that causes memory 
loss and severe problems in carrying out daily activities.",Alzheimer's disease,"memory 
loss and severe problems in carrying out daily activities.",associated_with,Alzheimer's disease-that,"memory 
loss and severe problems in carrying out daily activities.","It is a neurodegenerative illness-and the 
second most common type of dementia after [E1] Alzheimer's disease-that [/E1] causes [E2] memory 
loss and severe problems in carrying out daily activities. [/E2]"
"Furthermore, emerging evidence suggests 
a connection between gut dysbiosis and neurodegenerative disorders such as 
Alzheimer's disease.",Alzheimer's disease,neurodegenerative disorders,associated_with,Alzheimer's disease,neurodegenerative disorders,"Furthermore, emerging evidence suggests 
a connection between gut dysbiosis and [E2] neurodegenerative disorders [/E2] such as 
[E1] Alzheimer's disease [/E1]."
"Furthermore, emerging evidence suggests 
a connection between gut dysbiosis and neurodegenerative disorders such as 
Alzheimer's disease.",Alzheimer's disease,dysbiosis,associated_with,Alzheimer's disease,dysbiosis,"Furthermore, emerging evidence suggests 
a connection between gut [E2] dysbiosis [/E2] and neurodegenerative disorders such as 
[E1] Alzheimer's disease [/E1]."
"Brain atrophy over time, as measured by magnetic resonance imaging (MRI), has 
been shown to predict subsequent cognitive impairment among individuals who were 
cognitively normal when first evaluated, indicating that subtle brain atrophy 
associated with Alzheimer's disease (AD) may begin years before clinical 
symptoms appear.",Alzheimer's disease,atrophy,associated_with,Alzheimer's disease,atrophy,"Brain [E2] atrophy [/E2] over time, as measured by magnetic resonance imaging (MRI), has 
been shown to predict subsequent cognitive impairment among individuals who were 
cognitively normal when first evaluated, indicating that subtle brain atrophy 
associated with [E1] Alzheimer's disease [/E1] (AD) may begin years before clinical 
symptoms appear."
"Brain atrophy over time, as measured by magnetic resonance imaging (MRI), has 
been shown to predict subsequent cognitive impairment among individuals who were 
cognitively normal when first evaluated, indicating that subtle brain atrophy 
associated with Alzheimer's disease (AD) may begin years before clinical 
symptoms appear.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"Brain atrophy over time, as measured by magnetic resonance imaging (MRI), has 
been shown to predict subsequent cognitive impairment among individuals who were 
cognitively normal when first evaluated, indicating that subtle brain atrophy 
associated with [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) may begin years before clinical 
symptoms appear."
"Brain atrophy over time, as measured by magnetic resonance imaging (MRI), has 
been shown to predict subsequent cognitive impairment among individuals who were 
cognitively normal when first evaluated, indicating that subtle brain atrophy 
associated with Alzheimer's disease (AD) may begin years before clinical 
symptoms appear.",Alzheimer's disease,brain atrophy,associated_with,Alzheimer's disease,Brain atrophy,"[E2] Brain atrophy [/E2] over time, as measured by magnetic resonance imaging (MRI), has 
been shown to predict subsequent cognitive impairment among individuals who were 
cognitively normal when first evaluated, indicating that subtle brain atrophy 
associated with [E1] Alzheimer's disease [/E1] (AD) may begin years before clinical 
symptoms appear."
"Brain atrophy over time, as measured by magnetic resonance imaging (MRI), has 
been shown to predict subsequent cognitive impairment among individuals who were 
cognitively normal when first evaluated, indicating that subtle brain atrophy 
associated with Alzheimer's disease (AD) may begin years before clinical 
symptoms appear.",Alzheimer's disease,cognitive impairment,associated_with,Alzheimer's disease,cognitive impairment,"Brain atrophy over time, as measured by magnetic resonance imaging (MRI), has 
been shown to predict subsequent [E2] cognitive impairment [/E2] among individuals who were 
cognitively normal when first evaluated, indicating that subtle brain atrophy 
associated with [E1] Alzheimer's disease [/E1] (AD) may begin years before clinical 
symptoms appear."
"Alzheimer Disease (AD) represents a growing global health concern 
with profound socioeconomic implications, with predictions indicating a 
potential 50% increase in AD cases in Italy over the next 30 years.",Alzheimer's disease,ad,equivalent,Alzheimer Disease,AD,"[E1] Alzheimer Disease [/E1] ([E2] AD [/E2]) represents a growing global health concern 
with profound socioeconomic implications, with predictions indicating a 
potential 50% increase in AD cases in Italy over the next 30 years."
"Clinical 
differentiation of LBD from Alzheimer's disease (AD) remains complex due to 
symptom overlap, yet approximately 25% of dementia cases are diagnosed as LBD 
postmortem, primarily identified by the presence of ÃÂ±-synuclein aggregates, tau 
tangles, and amyloid plaques.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"Clinical 
differentiation of LBD from [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) remains complex due to 
symptom overlap, yet approximately 25% of dementia cases are diagnosed as LBD 
postmortem, primarily identified by the presence of ÃÂ±-synuclein aggregates, tau 
tangles, and amyloid plaques."
"Clinical 
differentiation of LBD from Alzheimer's disease (AD) remains complex due to 
symptom overlap, yet approximately 25% of dementia cases are diagnosed as LBD 
postmortem, primarily identified by the presence of ÃÂ±-synuclein aggregates, tau 
tangles, and amyloid plaques.",Alzheimer's disease,dementia,associated_with,Alzheimer's disease,dementia,"Clinical 
differentiation of LBD from [E1] Alzheimer's disease [/E1] (AD) remains complex due to 
symptom overlap, yet approximately 25% of [E2] dementia [/E2] cases are diagnosed as LBD 
postmortem, primarily identified by the presence of ÃÂ±-synuclein aggregates, tau 
tangles, and amyloid plaques."
"doi: 10.1186/s12883-025-04192-7.

Potential association between allergic disease and risk of Alzheimer's disease: 
insight from genetic analysis.",Alzheimer's disease,allergic disease,associated_with,Alzheimer's disease,allergic disease,"doi: 10.1186/s12883-025-04192-7.

Potential association between [E2] allergic disease [/E2] and risk of [E1] Alzheimer's disease [/E1]: 
insight from genetic analysis."
"Numerous evidence from observational studies indicated an association 
between allergic diseases and Alzheimer's Disease (AD).",Alzheimer's disease,ad,equivalent,Alzheimer's Disease,AD,"Numerous evidence from observational studies indicated an association 
between allergic diseases and [E1] Alzheimer's Disease [/E1] ([E2] AD [/E2])."
"Numerous evidence from observational studies indicated an association 
between allergic diseases and Alzheimer's Disease (AD).",Alzheimer's disease,allergic diseases,associated_with,Alzheimer's Disease,allergic diseases,"Numerous evidence from observational studies indicated an association 
between [E2] allergic diseases [/E2] and [E1] Alzheimer's Disease [/E1] (AD)."
"vjohn@mednet.ucla.edu.
(#)Contributed equally

Decreased expression of sirtuin 1 (SirT1) has been implicated in Alzheimer's 
disease (AD), and as we previously reported, is related to transcriptional 
repression by the major risk factor for sporadic AD, apolipoprotein E4 (ApoE4).",Alzheimer's disease,ad,equivalent,"Alzheimer's 
disease",AD,"vjohn@mednet.ucla.edu.
(#)Contributed equally

Decreased expression of sirtuin 1 (SirT1) has been implicated in [E1] Alzheimer's 
disease [/E1] ([E2] AD [/E2]), and as we previously reported, is related to transcriptional 
repression by the major risk factor for sporadic AD, apolipoprotein E4 (ApoE4)."
"Dementia 
encompasses Alzheimer's disease, Parkinson's disease, Huntington's disease, Lewy 
body dementia, mixed dementia, and various other diseases.",Alzheimer's disease,huntington's disease,ambiguous,Alzheimer's disease,Huntington's disease,"Dementia 
encompasses [E1] Alzheimer's disease [/E1], Parkinson's disease, [E2] Huntington's disease [/E2], Lewy 
body dementia, mixed dementia, and various other diseases."
"Dementia 
encompasses Alzheimer's disease, Parkinson's disease, Huntington's disease, Lewy 
body dementia, mixed dementia, and various other diseases.",Alzheimer's disease,lewy,ambiguous,Alzheimer's disease,Lewy,"Dementia 
encompasses [E1] Alzheimer's disease [/E1], Parkinson's disease, Huntington's disease, [E2] Lewy [/E2] 
body dementia, mixed dementia, and various other diseases."
"Dementia 
encompasses Alzheimer's disease, Parkinson's disease, Huntington's disease, Lewy 
body dementia, mixed dementia, and various other diseases.",Alzheimer's disease,dementia,associated_with,Alzheimer's disease,Dementia,"[E2] Dementia [/E2] 
encompasses [E1] Alzheimer's disease [/E1], Parkinson's disease, Huntington's disease, Lewy 
body dementia, mixed dementia, and various other diseases."
"Dementia 
encompasses Alzheimer's disease, Parkinson's disease, Huntington's disease, Lewy 
body dementia, mixed dementia, and various other diseases.",Alzheimer's disease,parkinson's disease,ambiguous,Alzheimer's disease,Parkinson's disease,"Dementia 
encompasses [E1] Alzheimer's disease [/E1], [E2] Parkinson's disease [/E2], Huntington's disease, Lewy 
body dementia, mixed dementia, and various other diseases."
"Among 
these, dichotic tests were identified as having the strongest association with 
cognitive decline, probable Alzheimer's disease, or dementia.",Alzheimer's disease,dementia,ambiguous,Alzheimer's disease,dementia,"Among 
these, dichotic tests were identified as having the strongest association with 
cognitive decline, probable [E1] Alzheimer's disease [/E1], or [E2] dementia [/E2]."
"Among 
these, dichotic tests were identified as having the strongest association with 
cognitive decline, probable Alzheimer's disease, or dementia.",Alzheimer's disease,cognitive decline,ambiguous,Alzheimer's disease,cognitive decline,"Among 
these, dichotic tests were identified as having the strongest association with 
[E2] cognitive decline [/E2], probable [E1] Alzheimer's disease [/E1], or dementia."
"Microglia-mediated neuroinflammation plays a critical role in the onset and 
progression of Alzheimer's disease.",Alzheimer's disease,neuroinflammation,associated_with,Alzheimer's disease,neuroinflammation,"Microglia-mediated [E2] neuroinflammation [/E2] plays a critical role in the onset and 
progression of [E1] Alzheimer's disease [/E1]."
"The primary outcome was overall dementia 
incidence, including vascular dementia, Alzheimer's disease, and other subtypes.",Alzheimer's disease,dementia,associated_with,Alzheimer's disease,dementia,"The primary outcome was overall [E2] dementia [/E2] 
incidence, including vascular dementia, [E1] Alzheimer's disease [/E1], and other subtypes."
"Reductions were observed in vascular 
dementia (0.8% vs. 2.0%; aHR 0.87), Alzheimer's dementia (1.1% vs. 3.2%; aHR, 
0.76), and all-cause mortality (6.8% vs. 15.4%; aHR, 0.92).",Alzheimer's disease,dementia,ambiguous,Alzheimer's dementia,dementia,"Reductions were observed in vascular 
[E2] dementia [/E2] (0.8% vs. 2.0%; aHR 0.87), [E1] Alzheimer's dementia [/E1] (1.1% vs. 3.2%; aHR, 
0.76), and all-cause mortality (6.8% vs. 15.4%; aHR, 0.92)."
"Secondary outcomes included 
dementia-related drug use and subtypes of dementia, such as Alzheimer's disease 
and vascular dementia.",Alzheimer's disease,dementia,associated_with,Alzheimer's disease,dementia,"Secondary outcomes included 
[E2] dementia [/E2]-related drug use and subtypes of dementia, such as [E1] Alzheimer's disease [/E1] 
and vascular dementia."
"Similar reductions were observed for 
dementia-related drug use (HR, 0.69; 95Ã¢Â? CI: 0.64-0.74; pÃ¢Â?Ã¢Â?.001), Alzheimer's 
disease (HR, 0.53; 95Ã¢Â? CI: 0.48-0.60; pÃ¢Â?Ã¢Â?.001), and vascular dementia (HR, 
0.52;",Alzheimer's disease,vascular dementia,ambiguous,"Alzheimer's 
disease",vascular dementia,"Similar reductions were observed for 
dementia-related drug use (HR, 0.69; 95Ã¢Â? CI: 0.64-0.74; pÃ¢Â?Ã¢Â?.001), [E1] Alzheimer's 
disease [/E1] (HR, 0.53; 95Ã¢Â? CI: 0.48-0.60; pÃ¢Â?Ã¢Â?.001), and [E2] vascular dementia [/E2] (HR, 
0.52;"
"Advanced glycation end-products (AGEs) formation in proteins 
are involved in healthy aging and a variety of diseases including Alzheimer's 
disease, atherosclerosis, and diabetic complications.",Alzheimer's disease,atherosclerosis,ambiguous,"Alzheimer's 
disease",atherosclerosis,"Advanced glycation end-products (AGEs) formation in proteins 
are involved in healthy aging and a variety of diseases including [E1] Alzheimer's 
disease [/E1], [E2] atherosclerosis [/E2], and diabetic complications."
"Advanced glycation end-products (AGEs) formation in proteins 
are involved in healthy aging and a variety of diseases including Alzheimer's 
disease, atherosclerosis, and diabetic complications.",Alzheimer's disease,diabetic complications,ambiguous,"Alzheimer's 
disease",diabetic complications,"Advanced glycation end-products (AGEs) formation in proteins 
are involved in healthy aging and a variety of diseases including [E1] Alzheimer's 
disease [/E1], atherosclerosis, and [E2] diabetic complications [/E2]."
"Blockage of CCL3 with neutralizing antibody reduces neuroinflammation and 
reverses Alzheimer disease phenotypes.",Alzheimer's disease,neuroinflammation,ambiguous,Alzheimer disease,neuroinflammation,"Blockage of CCL3 with neutralizing antibody reduces [E2] neuroinflammation [/E2] and 
reverses [E1] Alzheimer disease [/E1] phenotypes."
"Electronic address: xiehengge@163.com.cn.

BACKGROUND: Accumulating evidence indicates that neuroinflammation is involved 
in the pathogenesis of Alzheimer's disease (AD).",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"Electronic address: xiehengge@163.com.cn.

BACKGROUND: Accumulating evidence indicates that neuroinflammation is involved 
in the pathogenesis of [E1] Alzheimer's disease [/E1] ([E2] AD [/E2])."
"Electronic address: xiehengge@163.com.cn.

BACKGROUND: Accumulating evidence indicates that neuroinflammation is involved 
in the pathogenesis of Alzheimer's disease (AD).",Alzheimer's disease,neuroinflammation,associated_with,Alzheimer's disease,neuroinflammation,"Electronic address: xiehengge@163.com.cn.

BACKGROUND: Accumulating evidence indicates that [E2] neuroinflammation [/E2] is involved 
in the pathogenesis of [E1] Alzheimer's disease [/E1] (AD)."
"Furthermore, BSP 
supplementation enhances resistance to H2O2-induced oxidative and starvation 
stresses, attenuates the lead (Pb)-induced toxicity, and delays the onset of 
Alzheimer's phenotypes in flies.",Alzheimer's disease,toxicity,ambiguous,Alzheimer's phenotypes in flies.,toxicity,"Furthermore, BSP 
supplementation enhances resistance to H2O2-induced oxidative and starvation 
stresses, attenuates the lead (Pb)-induced [E2] toxicity [/E2], and delays the onset of 
[E1] Alzheimer's phenotypes in flies. [/E1]"
"Alzheimer's disease (AD) represents a progressive neurodegenerative disorder 
marked by complex pathologies.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"[E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) represents a progressive neurodegenerative disorder 
marked by complex pathologies."
"Alzheimer's disease (AD) represents a progressive neurodegenerative disorder 
marked by complex pathologies.",Alzheimer's disease,neurodegenerative disorder,associated_with,Alzheimer's disease,neurodegenerative disorder,"[E1] Alzheimer's disease [/E1] (AD) represents a progressive [E2] neurodegenerative disorder [/E2] 
marked by complex pathologies."
"The authors 
declare the following financial interests/personal relationships which may be 
considered as potential competing interests: PCD has received grant support by 
the Medical Research Council, the Lewy Body Society, AlzheimerÃ¢ÂÂs Society and 
Alzheimer's Research UK.",Alzheimer's disease,pcd,unrelated,,PCD,"The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [E2] PCD [/E2] has received grant support by the Medical Research Council, the Lewy Body Society, [E1] Alzheimer [/E1] Ã¢ÂÂs Society and Alzheimer's Research UK."
"This 
study aimed to determine whether MetS and its individual components increase the 
risk of YOD, including all-cause dementia, Alzheimer disease (AD), and vascular 
dementia (VaD).",Alzheimer's disease,ad,equivalent,Alzheimer disease,AD,"This 
study aimed to determine whether MetS and its individual components increase the 
risk of YOD, including all-cause dementia, [E1] Alzheimer disease [/E1] ([E2] AD [/E2]), and vascular 
dementia (VaD)."
"This 
study aimed to determine whether MetS and its individual components increase the 
risk of YOD, including all-cause dementia, Alzheimer disease (AD), and vascular 
dementia (VaD).",Alzheimer's disease,vad,ambiguous,Alzheimer disease,VaD,"This 
study aimed to determine whether MetS and its individual components increase the 
risk of YOD, including all-cause dementia, [E1] Alzheimer disease [/E1] (AD), and vascular 
dementia ([E2] VaD [/E2])."
"This 
study aimed to determine whether MetS and its individual components increase the 
risk of YOD, including all-cause dementia, Alzheimer disease (AD), and vascular 
dementia (VaD).",Alzheimer's disease,dementia,ambiguous,Alzheimer disease,dementia,"This 
study aimed to determine whether MetS and its individual components increase the 
risk of YOD, including all-cause [E2] dementia [/E2], [E1] Alzheimer disease [/E1] (AD), and vascular 
dementia (VaD)."
"This 
study aimed to determine whether MetS and its individual components increase the 
risk of YOD, including all-cause dementia, Alzheimer disease (AD), and vascular 
dementia (VaD).",Alzheimer's disease,yod,associated_with,Alzheimer disease,YOD,"This 
study aimed to determine whether MetS and its individual components increase the 
risk of [E2] YOD [/E2], including all-cause dementia, [E1] Alzheimer disease [/E1] (AD), and vascular 
dementia (VaD)."
"EPIC-Potsdam sub-cohort study: The early role of trace elements, oxidative 
stress, and anthropometrics in Alzheimer's disease and dementia onset.",Alzheimer's disease,dementia,ambiguous,Alzheimer's disease,dementia,"EPIC-Potsdam sub-cohort study: The early role of trace elements, oxidative 
stress, and anthropometrics in [E1] Alzheimer's disease [/E1] and [E2] dementia [/E2] onset."
"BackgroundSerum trace elements, anthropometric data, and oxidative stress 
markers are often altered in patients diagnosed with Alzheimer's disease (AD) or 
other types of dementia (OTD).",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"BackgroundSerum trace elements, anthropometric data, and oxidative stress 
markers are often altered in patients diagnosed with [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) or 
other types of dementia (OTD)."
"BackgroundSerum trace elements, anthropometric data, and oxidative stress 
markers are often altered in patients diagnosed with Alzheimer's disease (AD) or 
other types of dementia (OTD).",Alzheimer's disease,dementia,associated_with,Alzheimer's disease,dementia,"BackgroundSerum trace elements, anthropometric data, and oxidative stress 
markers are often altered in patients diagnosed with [E1] Alzheimer's disease [/E1] (AD) or 
other types of [E2] dementia [/E2] (OTD)."
"ObjectiveThis nested 
case-control study aims to investigate anthropometric data, serum trace 
elements, exchangeable copper (CuEXC), and oxidative stress markers to identify 
early associations with the risk of AD or OTD.MethodsFrom the European 
Prospective Investigation into Cancer and Nutrition-Potsdam cohort (DRKS-ID: 
DRKS00020593), the High Fat Diet, Microbiota, and Neuroinflammation in the 
Progression of Alzheimer study was generated.",Alzheimer's disease,cancer,unrelated,Alzheimer study,Cancer,"ObjectiveThis nested 
case-control study aims to investigate anthropometric data, serum trace 
elements, exchangeable copper (CuEXC), and oxidative stress markers to identify 
early associations with the risk of AD or OTD.MethodsFrom the European 
Prospective Investigation into [E2] Cancer [/E2] and Nutrition-Potsdam cohort (DRKS-ID: 
DRKS00020593), the High Fat Diet, Microbiota, and Neuroinflammation in the 
Progression of [E1] Alzheimer study [/E1] was generated."
"ObjectiveThis nested 
case-control study aims to investigate anthropometric data, serum trace 
elements, exchangeable copper (CuEXC), and oxidative stress markers to identify 
early associations with the risk of AD or OTD.MethodsFrom the European 
Prospective Investigation into Cancer and Nutrition-Potsdam cohort (DRKS-ID: 
DRKS00020593), the High Fat Diet, Microbiota, and Neuroinflammation in the 
Progression of Alzheimer study was generated.",Alzheimer's disease,neuroinflammation,associated_with,Alzheimer study,Neuroinflammation,"ObjectiveThis nested 
case-control study aims to investigate anthropometric data, serum trace 
elements, exchangeable copper (CuEXC), and oxidative stress markers to identify 
early associations with the risk of AD or OTD.MethodsFrom the European 
Prospective Investigation into Cancer and Nutrition-Potsdam cohort (DRKS-ID: 
DRKS00020593), the High Fat Diet, Microbiota, and [E2] Neuroinflammation [/E2] in the 
Progression of [E1] Alzheimer study [/E1] was generated."
"Background: Alzheimer's disease and related dementias (ADRD) are 
neurodegenerative disorders that afflict 1 in 9 older adults.",Alzheimer's disease,dementias,associated_with,Alzheimer's disease,dementias,"Background: [E1] Alzheimer's disease [/E1] and related [E2] dementias [/E2] (ADRD) are 
neurodegenerative disorders that afflict 1 in 9 older adults."
"Background: Alzheimer's disease and related dementias (ADRD) are 
neurodegenerative disorders that afflict 1 in 9 older adults.",Alzheimer's disease,neurodegenerative disorders,associated_with,Alzheimer's disease,neurodegenerative disorders,"Background: [E1] Alzheimer's disease [/E1] and related dementias (ADRD) are 
[E2] neurodegenerative disorders [/E2] that afflict 1 in 9 older adults."
"Background: Alzheimer's disease and related dementias (ADRD) are 
neurodegenerative disorders that afflict 1 in 9 older adults.",Alzheimer's disease,adrd,associated_with,Alzheimer's disease,ADRD,"Background: [E1] Alzheimer's disease [/E1] and related dementias ([E2] ADRD [/E2]) are 
neurodegenerative disorders that afflict 1 in 9 older adults."
"BackgroundThe alternative splicing (AS) of MAPT, which encodes Tau, in the adult 
human brain produces six major isoforms that play critical roles in the 
pathogenesis of tauopathies including Alzheimer's disease.",Alzheimer's disease,tauopathies,associated_with,Alzheimer's disease,tauopathies,"BackgroundThe alternative splicing (AS) of MAPT, which encodes Tau, in the adult 
human brain produces six major isoforms that play critical roles in the 
pathogenesis of [E2] tauopathies [/E2] including [E1] Alzheimer's disease [/E1]."
"BackgroundCurrent therapies for cognitive impairment, including Alzheimer's 
disease (AD) and mild cognitive impairment, are limited by a lack of universal 
treatment and adverse effects associated with polypharmacy.",Alzheimer's disease,ad,equivalent,"Alzheimer's 
disease",AD,"BackgroundCurrent therapies for cognitive impairment, including [E1] Alzheimer's 
disease [/E1] ([E2] AD [/E2]) and mild cognitive impairment, are limited by a lack of universal 
treatment and adverse effects associated with polypharmacy."
"BackgroundCurrent therapies for cognitive impairment, including Alzheimer's 
disease (AD) and mild cognitive impairment, are limited by a lack of universal 
treatment and adverse effects associated with polypharmacy.",Alzheimer's disease,cognitive impairment,associated_with,"Alzheimer's 
disease",cognitive impairment,"BackgroundCurrent therapies for [E2] cognitive impairment [/E2], including [E1] Alzheimer's 
disease [/E1] (AD) and mild cognitive impairment, are limited by a lack of universal 
treatment and adverse effects associated with polypharmacy."
"BackgroundThe involvement of microglia is likely to be pivotal in the 
pathogenesis of Alzheimer's disease (AD) by modulating the deposition of 
amyloid-ÃÂ² (AÃÂ²) plaques.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"BackgroundThe involvement of microglia is likely to be pivotal in the 
pathogenesis of [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) by modulating the deposition of 
amyloid-ÃÂ² (AÃÂ²) plaques."
"BackgroundLow-intensity focused ultrasound (LIFU), a non-invasive targeted brain 
stimulation technology, has shown promise for therapeutic applications in 
Alzheimer's disease (AD) patients.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"BackgroundLow-intensity focused ultrasound (LIFU), a non-invasive targeted brain 
stimulation technology, has shown promise for therapeutic applications in 
[E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) patients."
"BackgroundImpairments in orientation in space, time, and person occur frequently 
in Alzheimer's disease (AD) dementia.",Alzheimer's disease,dementia,associated_with,Alzheimer's disease,,"BackgroundImpairments in orientation in space, time, and person occur frequently 
in [E1] Alzheimer's disease [/E1] (AD) [E2] dementia [/E2]."
"BackgroundLecanemab, a monoclonal antibody targeting amyloid-ÃÂ² plaques, is 
FDA-approved for early Alzheimer's disease (AD) treatment.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"BackgroundLecanemab, a monoclonal antibody targeting amyloid-ÃÂ² plaques, is 
FDA-approved for early [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) treatment."
"ObjectiveThis study aims to integrate single-nuclei sequencing data from 
the Seattle Alzheimer's Disease Cortical Atlas (SEA-AD) with spatial 
transcriptomics to quantify cellular changes in the prefrontal cortex and 
temporal gyrus, regions vulnerable to AD neuropathological changes 
(ADNC).MethodsWe mapped differentially expressed genes (DEGs) and analyzed their 
interactions with pathological factors such as APOE expression and Lewy bodies.",Alzheimer's disease,lewy,unrelated,Alzheimer's Disease Cortical Atlas,Lewy,"ObjectiveThis study aims to integrate single-nuclei sequencing data from 
the Seattle [E1] Alzheimer's Disease Cortical Atlas [/E1] (SEA-AD) with spatial 
transcriptomics to quantify cellular changes in the prefrontal cortex and 
temporal gyrus, regions vulnerable to AD neuropathological changes 
(ADNC).MethodsWe mapped differentially expressed genes (DEGs) and analyzed their 
interactions with pathological factors such as APOE expression and [E2] Lewy [/E2] bodies."
"BackgroundNeuropsychological (NP) assessment is crucial for diagnosing prodromal 
and Alzheimer's disease and related dementia (ADRD) syndromes.",Alzheimer's disease,dementia,associated_with,Alzheimer's disease,dementia,"BackgroundNeuropsychological (NP) assessment is crucial for diagnosing prodromal 
and [E1] Alzheimer's disease [/E1] and related [E2] dementia [/E2] (ADRD) syndromes."
"BackgroundNeuropsychological (NP) assessment is crucial for diagnosing prodromal 
and Alzheimer's disease and related dementia (ADRD) syndromes.",Alzheimer's disease,adrd,associated_with,Alzheimer's disease,ADRD,"BackgroundNeuropsychological (NP) assessment is crucial for diagnosing prodromal 
and [E1] Alzheimer's disease [/E1] and related dementia ([E2] ADRD [/E2]) syndromes."
"Author information:
(1)Department of Neurology, Mayo Clinic, Rochester, MN, USA.
(2)Department of Laboratory Medicine and Pathology, University of Minnesota, 
Minneapolis, MN, USA.
(3)Department of Epidemiology and Prevention, Wake Forest University, 
Winston-Salem, NC, USA.
(4)Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.
(5)Department of Radiology, Mayo Clinic, Rochester, MN, USA.

BackgroundStudies suggest that plasma Alzheimer's disease (AD) biomarkers may 
aid in the overall diagnosis of AD, but their utility among patients with 
atypical clinical presentations of AD are unknown.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"Author information:
(1)Department of Neurology, Mayo Clinic, Rochester, MN, USA.
(2)Department of Laboratory Medicine and Pathology, University of Minnesota, 
Minneapolis, MN, USA.
(3)Department of Epidemiology and Prevention, Wake Forest University, 
Winston-Salem, NC, USA.
(4)Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.
(5)Department of Radiology, Mayo Clinic, Rochester, MN, USA.

BackgroundStudies suggest that plasma [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) biomarkers may 
aid in the overall diagnosis of AD, but their utility among patients with 
atypical clinical presentations of AD are unknown."
"Proteins involved 
in the pathogenesis of Parkinson's disease (PD), Alzheimer's disease (AD), and 
amyotrophic lateral sclerosis (ALS) condensed and underwent ATP-dependent liquid 
phase separation in vitro.",Alzheimer's disease,amyotrophic lateral sclerosis,ambiguous,Alzheimer's disease,amyotrophic lateral sclerosis,"Proteins involved 
in the pathogenesis of Parkinson's disease (PD), [E1] Alzheimer's disease [/E1] (AD), and 
[E2] amyotrophic lateral sclerosis [/E2] (ALS) condensed and underwent ATP-dependent liquid 
phase separation in vitro."
"Proteins involved 
in the pathogenesis of Parkinson's disease (PD), Alzheimer's disease (AD), and 
amyotrophic lateral sclerosis (ALS) condensed and underwent ATP-dependent liquid 
phase separation in vitro.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"Proteins involved 
in the pathogenesis of Parkinson's disease (PD), [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]), and 
amyotrophic lateral sclerosis (ALS) condensed and underwent ATP-dependent liquid 
phase separation in vitro."
"Proteins involved 
in the pathogenesis of Parkinson's disease (PD), Alzheimer's disease (AD), and 
amyotrophic lateral sclerosis (ALS) condensed and underwent ATP-dependent liquid 
phase separation in vitro.",Alzheimer's disease,pd,ambiguous,Alzheimer's disease,PD,"Proteins involved 
in the pathogenesis of Parkinson's disease ([E2] PD [/E2]), [E1] Alzheimer's disease [/E1] (AD), and 
amyotrophic lateral sclerosis (ALS) condensed and underwent ATP-dependent liquid 
phase separation in vitro."
"Proteins involved 
in the pathogenesis of Parkinson's disease (PD), Alzheimer's disease (AD), and 
amyotrophic lateral sclerosis (ALS) condensed and underwent ATP-dependent liquid 
phase separation in vitro.",Alzheimer's disease,parkinson's disease,ambiguous,Alzheimer's disease,Parkinson's disease,"Proteins involved 
in the pathogenesis of [E2] Parkinson's disease [/E2] (PD), [E1] Alzheimer's disease [/E1] (AD), and 
amyotrophic lateral sclerosis (ALS) condensed and underwent ATP-dependent liquid 
phase separation in vitro."
"Proteins involved 
in the pathogenesis of Parkinson's disease (PD), Alzheimer's disease (AD), and 
amyotrophic lateral sclerosis (ALS) condensed and underwent ATP-dependent liquid 
phase separation in vitro.",Alzheimer's disease,als,ambiguous,Alzheimer's disease,ALS,"Proteins involved 
in the pathogenesis of Parkinson's disease (PD), [E1] Alzheimer's disease [/E1] (AD), and 
amyotrophic lateral sclerosis ([E2] ALS [/E2]) condensed and underwent ATP-dependent liquid 
phase separation in vitro."
"The core target proteins among 
the duplicate targets were primarily involved in pathways related to cancer, 
lipid and atherosclerosis, hepatitis B, proteoglycans in cancer, and Alzheimer's 
disease.",Alzheimer's disease,atherosclerosis,ambiguous,"Alzheimer's 
disease",atherosclerosis,"The core target proteins among 
the duplicate targets were primarily involved in pathways related to cancer, 
lipid and [E2] atherosclerosis [/E2], hepatitis B, proteoglycans in cancer, and [E1] Alzheimer's 
disease [/E1]."
"The core target proteins among 
the duplicate targets were primarily involved in pathways related to cancer, 
lipid and atherosclerosis, hepatitis B, proteoglycans in cancer, and Alzheimer's 
disease.",Alzheimer's disease,cancer,ambiguous,"Alzheimer's 
disease",cancer,"The core target proteins among 
the duplicate targets were primarily involved in pathways related to [E2] cancer [/E2], 
lipid and atherosclerosis, hepatitis B, proteoglycans in cancer, and [E1] Alzheimer's 
disease [/E1]."
"The core target proteins among 
the duplicate targets were primarily involved in pathways related to cancer, 
lipid and atherosclerosis, hepatitis B, proteoglycans in cancer, and Alzheimer's 
disease.",Alzheimer's disease,hepatitis b,ambiguous,"Alzheimer's 
disease",hepatitis B,"The core target proteins among 
the duplicate targets were primarily involved in pathways related to cancer, 
lipid and atherosclerosis, [E2] hepatitis B [/E2], proteoglycans in cancer, and [E1] Alzheimer's 
disease [/E1]."
"Oral 
administration of ZSS hot water extract ameliorated AÃÂ² and tau pathology and 
cognitive impairment in mouse models of Alzheimer's disease and frontotemporal 
dementia.",Alzheimer's disease,dementia,ambiguous,Alzheimer's disease and frontotemporal,dementia,"Oral 
administration of ZSS hot water extract ameliorated AÃÂ² and tau pathology and 
cognitive impairment in mouse models of [E1] Alzheimer's disease and frontotemporal [/E1] 
[E2] dementia [/E2]."
"Oral 
administration of ZSS hot water extract ameliorated AÃÂ² and tau pathology and 
cognitive impairment in mouse models of Alzheimer's disease and frontotemporal 
dementia.",Alzheimer's disease,cognitive impairment,associated_with,Alzheimer's disease and frontotemporal,cognitive impairment,"Oral 
administration of ZSS hot water extract ameliorated AÃÂ² and tau pathology and 
[E2] cognitive impairment [/E2] in mouse models of [E1] Alzheimer's disease and frontotemporal [/E1] 
dementia."
"Virtual reality as a complementary therapy in the rehabilitation of balance and 
gait disorders in patients with mild cognitive impairment and Alzheimer's 
disease: Systematic review.",Alzheimer's disease,cognitive impairment,ambiguous,"Alzheimer's 
disease",cognitive impairment,"Virtual reality as a complementary therapy in the rehabilitation of balance and 
gait disorders in patients with mild [E2] cognitive impairment [/E2] and [E1] Alzheimer's 
disease [/E1]: Systematic review."
"Virtual reality as a complementary therapy in the rehabilitation of balance and 
gait disorders in patients with mild cognitive impairment and Alzheimer's 
disease: Systematic review.",Alzheimer's disease,gait disorders,associated_with,"Alzheimer's 
disease",gait disorders,"Virtual reality as a complementary therapy in the rehabilitation of balance and 
[E2] gait disorders [/E2] in patients with mild cognitive impairment and [E1] Alzheimer's 
disease [/E1]: Systematic review."
"ObjectiveTo analyse the benefits of virtual reality in the management of balance 
and gait disorders in people with Alzheimer's disease and cognitive 
impairment.",Alzheimer's disease,gait disorders,associated_with,"Alzheimer's disease and cognitive 
impairment",gait disorders,"ObjectiveTo analyse the benefits of virtual reality in the management of balance 
and [E2] gait disorders [/E2] in people with [E1] Alzheimer's disease and cognitive 
impairment [/E1]."
"The inclusion criteria were: 
randomised, cross-sectional, quasi-experimental controlled clinical trials 
involving patients diagnosed with mild cognitive impairment, dementia and 
Alzheimer's disease with a score of Ã¢Â?3 on the MMSE test and age Ã¢Â?0 years, and 
interventions conducted with virtual reality and conventional physiotherapy for 
the treatment of balance and gait disorders.",Alzheimer's disease,dementia,ambiguous,Alzheimer's disease,dementia,"The inclusion criteria were: 
randomised, cross-sectional, quasi-experimental controlled clinical trials 
involving patients diagnosed with mild cognitive impairment, [E2] dementia [/E2] and 
[E1] Alzheimer's disease [/E1] with a score of Ã¢Â?3 on the MMSE test and age Ã¢Â?0 years, and 
interventions conducted with virtual reality and conventional physiotherapy for 
the treatment of balance and gait disorders."
"The inclusion criteria were: 
randomised, cross-sectional, quasi-experimental controlled clinical trials 
involving patients diagnosed with mild cognitive impairment, dementia and 
Alzheimer's disease with a score of Ã¢Â?3 on the MMSE test and age Ã¢Â?0 years, and 
interventions conducted with virtual reality and conventional physiotherapy for 
the treatment of balance and gait disorders.",Alzheimer's disease,cognitive impairment,ambiguous,Alzheimer's disease,cognitive impairment,"The inclusion criteria were: 
randomised, cross-sectional, quasi-experimental controlled clinical trials 
involving patients diagnosed with mild [E2] cognitive impairment [/E2], dementia and 
[E1] Alzheimer's disease [/E1] with a score of Ã¢Â?3 on the MMSE test and age Ã¢Â?0 years, and 
interventions conducted with virtual reality and conventional physiotherapy for 
the treatment of balance and gait disorders."
"The inclusion criteria were: 
randomised, cross-sectional, quasi-experimental controlled clinical trials 
involving patients diagnosed with mild cognitive impairment, dementia and 
Alzheimer's disease with a score of Ã¢Â?3 on the MMSE test and age Ã¢Â?0 years, and 
interventions conducted with virtual reality and conventional physiotherapy for 
the treatment of balance and gait disorders.",Alzheimer's disease,gait disorders,ambiguous,Alzheimer's disease,gait disorders,"The inclusion criteria were: 
randomised, cross-sectional, quasi-experimental controlled clinical trials 
involving patients diagnosed with mild cognitive impairment, dementia and 
[E1] Alzheimer's disease [/E1] with a score of Ã¢Â?3 on the MMSE test and age Ã¢Â?0 years, and 
interventions conducted with virtual reality and conventional physiotherapy for 
the treatment of balance and [E2] gait disorders [/E2]."
"ConclusionStudies suggest that 
interventions based on virtual environments in older adults with early 
Alzheimer's disease can improve balance and gait impairments, postural control 
and executive function, delaying the deterioration caused by the disease.",Alzheimer's disease,gait impairments,associated_with,Alzheimer's disease,gait impairments,"ConclusionStudies suggest that 
interventions based on virtual environments in older adults with early 
[E1] Alzheimer's disease [/E1] can improve balance and [E2] gait impairments [/E2], postural control 
and executive function, delaying the deterioration caused by the disease."
"Elevated levels of circulating C1R protein increased the odds of 
developing Alzheimer's disease (AD), while PILRA and CELA2A were estimated to 
protect against the pathogenesis of AD; genetically predicted increase of 
ÃÂ±-synuclein and APOE elevated the occurrence of Dementia of Lewy Bodies (DLB); 
elevated level of circulating CRP was assessed to increase the onset of vascular 
dementia (VD).",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"Elevated levels of circulating C1R protein increased the odds of 
developing [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]), while PILRA and CELA2A were estimated to 
protect against the pathogenesis of AD; genetically predicted increase of 
ÃÂ±-synuclein and APOE elevated the occurrence of Dementia of Lewy Bodies (DLB); 
elevated level of circulating CRP was assessed to increase the onset of vascular 
dementia (VD)."
"Elevated levels of circulating C1R protein increased the odds of 
developing Alzheimer's disease (AD), while PILRA and CELA2A were estimated to 
protect against the pathogenesis of AD; genetically predicted increase of 
ÃÂ±-synuclein and APOE elevated the occurrence of Dementia of Lewy Bodies (DLB); 
elevated level of circulating CRP was assessed to increase the onset of vascular 
dementia (VD).",Alzheimer's disease,dlb,ambiguous,Alzheimer's disease,DLB,"Elevated levels of circulating C1R protein increased the odds of 
developing [E1] Alzheimer's disease [/E1] (AD), while PILRA and CELA2A were estimated to 
protect against the pathogenesis of AD; genetically predicted increase of 
ÃÂ±-synuclein and APOE elevated the occurrence of Dementia of Lewy Bodies ([E2] DLB [/E2]); 
elevated level of circulating CRP was assessed to increase the onset of vascular 
dementia (VD)."
"Elevated levels of circulating C1R protein increased the odds of 
developing Alzheimer's disease (AD), while PILRA and CELA2A were estimated to 
protect against the pathogenesis of AD; genetically predicted increase of 
ÃÂ±-synuclein and APOE elevated the occurrence of Dementia of Lewy Bodies (DLB); 
elevated level of circulating CRP was assessed to increase the onset of vascular 
dementia (VD).",Alzheimer's disease,dementia,ambiguous,Alzheimer's disease,Dementia,"Elevated levels of circulating C1R protein increased the odds of 
developing [E1] Alzheimer's disease [/E1] (AD), while PILRA and CELA2A were estimated to 
protect against the pathogenesis of AD; genetically predicted increase of 
ÃÂ±-synuclein and APOE elevated the occurrence of [E2] Dementia [/E2] of Lewy Bodies (DLB); 
elevated level of circulating CRP was assessed to increase the onset of vascular 
dementia (VD)."
"Alzheimer's Disease (AD) is a neurodegenerative condition 
characterised by cognitive decline and memory impairment.",Alzheimer's disease,ad,equivalent,Alzheimer's Disease,AD,"[E1] Alzheimer's Disease [/E1] ([E2] AD [/E2]) is a neurodegenerative condition 
characterised by cognitive decline and memory impairment."
"Alzheimer's Disease (AD) is a neurodegenerative condition 
characterised by cognitive decline and memory impairment.",Alzheimer's disease,memory impairment,associated_with,Alzheimer's Disease,memory impairment,"[E1] Alzheimer's Disease [/E1] (AD) is a neurodegenerative condition 
characterised by cognitive decline and [E2] memory impairment [/E2]."
"Alzheimer's Disease (AD) is a neurodegenerative condition 
characterised by cognitive decline and memory impairment.",Alzheimer's disease,cognitive decline,associated_with,Alzheimer's Disease,cognitive decline,"[E1] Alzheimer's Disease [/E1] (AD) is a neurodegenerative condition 
characterised by [E2] cognitive decline [/E2] and memory impairment."
"Alzheimer's disease (AD), a prevalent neurodegenerative disorder, represents a 
significant global health challenge, characterized by cognitive decline and 
neuroinflammation.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"[E1] Alzheimer's disease [/E1] ([E2] AD [/E2]), a prevalent neurodegenerative disorder, represents a 
significant global health challenge, characterized by cognitive decline and 
neuroinflammation."
"Alzheimer's disease (AD), a prevalent neurodegenerative disorder, represents a 
significant global health challenge, characterized by cognitive decline and 
neuroinflammation.",Alzheimer's disease,neuroinflammation,associated_with,Alzheimer's disease,neuroinflammation,"[E1] Alzheimer's disease [/E1] (AD), a prevalent neurodegenerative disorder, represents a 
significant global health challenge, characterized by cognitive decline and 
[E2] neuroinflammation [/E2]."
"Alzheimer's disease (AD), a prevalent neurodegenerative disorder, represents a 
significant global health challenge, characterized by cognitive decline and 
neuroinflammation.",Alzheimer's disease,cognitive decline,associated_with,Alzheimer's disease,cognitive decline,"[E1] Alzheimer's disease [/E1] (AD), a prevalent neurodegenerative disorder, represents a 
significant global health challenge, characterized by [E2] cognitive decline [/E2] and 
neuroinflammation."
"Alzheimer's disease (AD), a prevalent neurodegenerative disorder, represents a 
significant global health challenge, characterized by cognitive decline and 
neuroinflammation.",Alzheimer's disease,neurodegenerative disorder,associated_with,Alzheimer's disease,neurodegenerative disorder,"[E1] Alzheimer's disease [/E1] (AD), a prevalent [E2] neurodegenerative disorder [/E2], represents a 
significant global health challenge, characterized by cognitive decline and 
neuroinflammation."
"Genes related to Alzheimer's 
disease (AD), Parkinson's disease (PD), and Huntington's disease (HD) were 
gathered using online databases.",Alzheimer's disease,ad,equivalent,"Alzheimer's 
disease",AD,"Genes related to [E1] Alzheimer's 
disease [/E1] ([E2] AD [/E2]), Parkinson's disease (PD), and Huntington's disease (HD) were 
gathered using online databases."
"Genes related to Alzheimer's 
disease (AD), Parkinson's disease (PD), and Huntington's disease (HD) were 
gathered using online databases.",Alzheimer's disease,pd,ambiguous,"Alzheimer's 
disease",PD,"Genes related to [E1] Alzheimer's 
disease [/E1] (AD), Parkinson's disease ([E2] PD [/E2]), and Huntington's disease (HD) were 
gathered using online databases."
"Genes related to Alzheimer's 
disease (AD), Parkinson's disease (PD), and Huntington's disease (HD) were 
gathered using online databases.",Alzheimer's disease,huntington's disease,ambiguous,"Alzheimer's 
disease",Huntington's disease,"Genes related to [E1] Alzheimer's 
disease [/E1] (AD), Parkinson's disease (PD), and [E2] Huntington's disease [/E2] (HD) were 
gathered using online databases."
"Genes related to Alzheimer's 
disease (AD), Parkinson's disease (PD), and Huntington's disease (HD) were 
gathered using online databases.",Alzheimer's disease,hd,ambiguous,"Alzheimer's 
disease",HD,"Genes related to [E1] Alzheimer's 
disease [/E1] (AD), Parkinson's disease (PD), and Huntington's disease ([E2] HD [/E2]) were 
gathered using online databases."
"Genes related to Alzheimer's 
disease (AD), Parkinson's disease (PD), and Huntington's disease (HD) were 
gathered using online databases.",Alzheimer's disease,parkinson's disease,ambiguous,"Alzheimer's 
disease",Parkinson's disease,"Genes related to [E1] Alzheimer's 
disease [/E1] (AD), [E2] Parkinson's disease [/E2] (PD), and Huntington's disease (HD) were 
gathered using online databases."
"We highlight key 
innovations in EVs' molecular design, characterization, and deployment for 
treating diseases including Alzheimer's disease, infectious diseases, and 
cancers.",Alzheimer's disease,cancers,ambiguous,Alzheimer's disease,cancers,"We highlight key 
innovations in EVs' molecular design, characterization, and deployment for 
treating diseases including [E1] Alzheimer's disease [/E1], infectious diseases, and 
[E2] cancers [/E2]."
"We invited experts 
in the study of Alzheimer's disease and Related Disorders (ADRDs) to express 
their views on this paradigmatic shift in dementia management.",Alzheimer's disease,dementia,associated_with,Alzheimer's disease,dementia,"We invited experts 
in the study of [E1] Alzheimer's disease [/E1] and Related Disorders (ADRDs) to express 
their views on this paradigmatic shift in [E2] dementia [/E2] management."
"This breakthrough could influence 
the development of therapeutic leads for combating diabetes, cancer, and 
Alzheimer's disease.",Alzheimer's disease,"diabetes, cancer",ambiguous,Alzheimer's disease,"diabetes, cancer","This breakthrough could influence 
the development of therapeutic leads for combating [E2] diabetes, cancer [/E2], and 
[E1] Alzheimer's disease [/E1]."
"This review proposes a discussion on: (1) the complex role of 
distinct phenotypes of enteric glial cells involved in neurodegenerative 
diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD), 
amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and multiple 
sclerosis (MS); and (2) innovative strategies such as IDO/TDO inhibitors, Brazil 
nuts, caffeic acid, polyphenols, among others, that act on EGCs and have the 
potential to treat neurodegenerative diseases.",Alzheimer's disease,neurodegenerative diseases,associated_with,Alzheimer's disease,neurodegenerative diseases,"This review proposes a discussion on: (1) the complex role of 
distinct phenotypes of enteric glial cells involved in neurodegenerative 
diseases, such as Parkinson's disease (PD), [E1] Alzheimer's disease [/E1] (AD), 
amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and multiple 
sclerosis (MS); and (2) innovative strategies such as IDO/TDO inhibitors, Brazil 
nuts, caffeic acid, polyphenols, among others, that act on EGCs and have the 
potential to treat [E2] neurodegenerative diseases [/E2]."
"This review proposes a discussion on: (1) the complex role of 
distinct phenotypes of enteric glial cells involved in neurodegenerative 
diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD), 
amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and multiple 
sclerosis (MS); and (2) innovative strategies such as IDO/TDO inhibitors, Brazil 
nuts, caffeic acid, polyphenols, among others, that act on EGCs and have the 
potential to treat neurodegenerative diseases.",Alzheimer's disease,amyotrophic lateral sclerosis,ambiguous,Alzheimer's disease,amyotrophic lateral sclerosis,"This review proposes a discussion on: (1) the complex role of 
distinct phenotypes of enteric glial cells involved in neurodegenerative 
diseases, such as Parkinson's disease (PD), [E1] Alzheimer's disease [/E1] (AD), 
[E2] amyotrophic lateral sclerosis [/E2] (ALS), Huntington's disease (HD) and multiple 
sclerosis (MS); and (2) innovative strategies such as IDO/TDO inhibitors, Brazil 
nuts, caffeic acid, polyphenols, among others, that act on EGCs and have the 
potential to treat neurodegenerative diseases."
"This review proposes a discussion on: (1) the complex role of 
distinct phenotypes of enteric glial cells involved in neurodegenerative 
diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD), 
amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and multiple 
sclerosis (MS); and (2) innovative strategies such as IDO/TDO inhibitors, Brazil 
nuts, caffeic acid, polyphenols, among others, that act on EGCs and have the 
potential to treat neurodegenerative diseases.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"This review proposes a discussion on: (1) the complex role of 
distinct phenotypes of enteric glial cells involved in neurodegenerative 
diseases, such as Parkinson's disease (PD), [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]), 
amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and multiple 
sclerosis (MS); and (2) innovative strategies such as IDO/TDO inhibitors, Brazil 
nuts, caffeic acid, polyphenols, among others, that act on EGCs and have the 
potential to treat neurodegenerative diseases."
"This review proposes a discussion on: (1) the complex role of 
distinct phenotypes of enteric glial cells involved in neurodegenerative 
diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD), 
amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and multiple 
sclerosis (MS); and (2) innovative strategies such as IDO/TDO inhibitors, Brazil 
nuts, caffeic acid, polyphenols, among others, that act on EGCs and have the 
potential to treat neurodegenerative diseases.",Alzheimer's disease,pd,ambiguous,Alzheimer's disease,PD,"This review proposes a discussion on: (1) the complex role of 
distinct phenotypes of enteric glial cells involved in neurodegenerative 
diseases, such as Parkinson's disease ([E2] PD [/E2]), [E1] Alzheimer's disease [/E1] (AD), 
amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and multiple 
sclerosis (MS); and (2) innovative strategies such as IDO/TDO inhibitors, Brazil 
nuts, caffeic acid, polyphenols, among others, that act on EGCs and have the 
potential to treat neurodegenerative diseases."
"This review proposes a discussion on: (1) the complex role of 
distinct phenotypes of enteric glial cells involved in neurodegenerative 
diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD), 
amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and multiple 
sclerosis (MS); and (2) innovative strategies such as IDO/TDO inhibitors, Brazil 
nuts, caffeic acid, polyphenols, among others, that act on EGCs and have the 
potential to treat neurodegenerative diseases.",Alzheimer's disease,huntington's disease,ambiguous,Alzheimer's disease,Huntington's disease,"This review proposes a discussion on: (1) the complex role of 
distinct phenotypes of enteric glial cells involved in neurodegenerative 
diseases, such as Parkinson's disease (PD), [E1] Alzheimer's disease [/E1] (AD), 
amyotrophic lateral sclerosis (ALS), [E2] Huntington's disease [/E2] (HD) and multiple 
sclerosis (MS); and (2) innovative strategies such as IDO/TDO inhibitors, Brazil 
nuts, caffeic acid, polyphenols, among others, that act on EGCs and have the 
potential to treat neurodegenerative diseases."
"This review proposes a discussion on: (1) the complex role of 
distinct phenotypes of enteric glial cells involved in neurodegenerative 
diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD), 
amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and multiple 
sclerosis (MS); and (2) innovative strategies such as IDO/TDO inhibitors, Brazil 
nuts, caffeic acid, polyphenols, among others, that act on EGCs and have the 
potential to treat neurodegenerative diseases.",Alzheimer's disease,hd,ambiguous,Alzheimer's disease,HD,"This review proposes a discussion on: (1) the complex role of 
distinct phenotypes of enteric glial cells involved in neurodegenerative 
diseases, such as Parkinson's disease (PD), [E1] Alzheimer's disease [/E1] (AD), 
amyotrophic lateral sclerosis (ALS), Huntington's disease ([E2] HD [/E2]) and multiple 
sclerosis (MS); and (2) innovative strategies such as IDO/TDO inhibitors, Brazil 
nuts, caffeic acid, polyphenols, among others, that act on EGCs and have the 
potential to treat neurodegenerative diseases."
"This review proposes a discussion on: (1) the complex role of 
distinct phenotypes of enteric glial cells involved in neurodegenerative 
diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD), 
amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and multiple 
sclerosis (MS); and (2) innovative strategies such as IDO/TDO inhibitors, Brazil 
nuts, caffeic acid, polyphenols, among others, that act on EGCs and have the 
potential to treat neurodegenerative diseases.",Alzheimer's disease,parkinson's disease,ambiguous,Alzheimer's disease,Parkinson's disease,"This review proposes a discussion on: (1) the complex role of 
distinct phenotypes of enteric glial cells involved in neurodegenerative 
diseases, such as [E2] Parkinson's disease [/E2] (PD), [E1] Alzheimer's disease [/E1] (AD), 
amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and multiple 
sclerosis (MS); and (2) innovative strategies such as IDO/TDO inhibitors, Brazil 
nuts, caffeic acid, polyphenols, among others, that act on EGCs and have the 
potential to treat neurodegenerative diseases."
"This review proposes a discussion on: (1) the complex role of 
distinct phenotypes of enteric glial cells involved in neurodegenerative 
diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD), 
amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and multiple 
sclerosis (MS); and (2) innovative strategies such as IDO/TDO inhibitors, Brazil 
nuts, caffeic acid, polyphenols, among others, that act on EGCs and have the 
potential to treat neurodegenerative diseases.",Alzheimer's disease,als,ambiguous,Alzheimer's disease,ALS,"This review proposes a discussion on: (1) the complex role of 
distinct phenotypes of enteric glial cells involved in neurodegenerative 
diseases, such as Parkinson's disease (PD), [E1] Alzheimer's disease [/E1] (AD), 
amyotrophic lateral sclerosis ([E2] ALS [/E2]), Huntington's disease (HD) and multiple 
sclerosis (MS); and (2) innovative strategies such as IDO/TDO inhibitors, Brazil 
nuts, caffeic acid, polyphenols, among others, that act on EGCs and have the 
potential to treat neurodegenerative diseases."
"Chronic exposure to herbicides, weedicides, and pesticides is associated with 
the onset and progress of neurodegenerative disorders such as Parkinson's 
disease (PD), Alzheimer's disease (AD), and Amyotrophic Lateral Sclerosis (ALS).",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"Chronic exposure to herbicides, weedicides, and pesticides is associated with 
the onset and progress of neurodegenerative disorders such as Parkinson's 
disease (PD), [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]), and Amyotrophic Lateral Sclerosis (ALS)."
"Chronic exposure to herbicides, weedicides, and pesticides is associated with 
the onset and progress of neurodegenerative disorders such as Parkinson's 
disease (PD), Alzheimer's disease (AD), and Amyotrophic Lateral Sclerosis (ALS).",Alzheimer's disease,pd,ambiguous,Alzheimer's disease,PD,"Chronic exposure to herbicides, weedicides, and pesticides is associated with 
the onset and progress of neurodegenerative disorders such as Parkinson's 
disease ([E2] PD [/E2]), [E1] Alzheimer's disease [/E1] (AD), and Amyotrophic Lateral Sclerosis (ALS)."
"Chronic exposure to herbicides, weedicides, and pesticides is associated with 
the onset and progress of neurodegenerative disorders such as Parkinson's 
disease (PD), Alzheimer's disease (AD), and Amyotrophic Lateral Sclerosis (ALS).",Alzheimer's disease,"parkinson's 
disease",ambiguous,Alzheimer's disease,"Parkinson's 
disease","Chronic exposure to herbicides, weedicides, and pesticides is associated with 
the onset and progress of neurodegenerative disorders such as [E2] Parkinson's 
disease [/E2] (PD), [E1] Alzheimer's disease [/E1] (AD), and Amyotrophic Lateral Sclerosis (ALS)."
"Chronic exposure to herbicides, weedicides, and pesticides is associated with 
the onset and progress of neurodegenerative disorders such as Parkinson's 
disease (PD), Alzheimer's disease (AD), and Amyotrophic Lateral Sclerosis (ALS).",Alzheimer's disease,neurodegenerative disorders,associated_with,Alzheimer's disease,neurodegenerative disorders,"Chronic exposure to herbicides, weedicides, and pesticides is associated with 
the onset and progress of [E2] neurodegenerative disorders [/E2] such as Parkinson's 
disease (PD), [E1] Alzheimer's disease [/E1] (AD), and Amyotrophic Lateral Sclerosis (ALS)."
"Chronic exposure to herbicides, weedicides, and pesticides is associated with 
the onset and progress of neurodegenerative disorders such as Parkinson's 
disease (PD), Alzheimer's disease (AD), and Amyotrophic Lateral Sclerosis (ALS).",Alzheimer's disease,als,ambiguous,Alzheimer's disease,ALS,"Chronic exposure to herbicides, weedicides, and pesticides is associated with 
the onset and progress of neurodegenerative disorders such as Parkinson's 
disease (PD), [E1] Alzheimer's disease [/E1] (AD), and Amyotrophic Lateral Sclerosis ([E2] ALS [/E2])."
"Alzheimer's disease (AD) is a progressive neurodegenerative disorder 
characterized by cognitive decline and memory loss, with amyloid-beta (AÃÂ²) 
plaques and acetylcholine deficits being central pathological features.",Alzheimer's disease,"amyloid-beta (aÃÂ²) 
plaques and acetylcholine",associated_with,Alzheimer's disease,,"[E1] Alzheimer's disease [/E1] (AD) is a progressive neurodegenerative disorder 
characterized by cognitive decline and memory loss, with [E2] amyloid-bet [/E2]a (AÃÂ²) 
plaques and acetylcholine deficits being central pathological features."
"Alzheimer's disease (AD) is a progressive neurodegenerative disorder 
characterized by cognitive decline and memory loss, with amyloid-beta (AÃÂ²) 
plaques and acetylcholine deficits being central pathological features.",Alzheimer's disease,memory loss,associated_with,Alzheimer's disease,memory loss,"[E1] Alzheimer's disease [/E1] (AD) is a progressive neurodegenerative disorder 
characterized by cognitive decline and [E2] memory loss [/E2], with amyloid-beta (AÃÂ²) 
plaques and acetylcholine deficits being central pathological features."
"Alzheimer's disease (AD) is a progressive neurodegenerative disorder 
characterized by cognitive decline and memory loss, with amyloid-beta (AÃÂ²) 
plaques and acetylcholine deficits being central pathological features.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"[E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) is a progressive neurodegenerative disorder 
characterized by cognitive decline and memory loss, with amyloid-beta (AÃÂ²) 
plaques and acetylcholine deficits being central pathological features."
"Alzheimer's disease (AD) is a progressive neurodegenerative disorder 
characterized by cognitive decline and memory loss, with amyloid-beta (AÃÂ²) 
plaques and acetylcholine deficits being central pathological features.",Alzheimer's disease,cognitive decline,associated_with,Alzheimer's disease,cognitive decline,"[E1] Alzheimer's disease [/E1] (AD) is a progressive neurodegenerative disorder 
characterized by [E2] cognitive decline [/E2] and memory loss, with amyloid-beta (AÃÂ²) 
plaques and acetylcholine deficits being central pathological features."
"Alzheimer's disease (AD) is a progressive neurodegenerative disorder 
characterized by cognitive decline and memory loss, with amyloid-beta (AÃÂ²) 
plaques and acetylcholine deficits being central pathological features.",Alzheimer's disease,neurodegenerative disorder,associated_with,Alzheimer's disease,neurodegenerative disorder,"[E1] Alzheimer's disease [/E1] (AD) is a progressive [E2] neurodegenerative disorder [/E2] 
characterized by cognitive decline and memory loss, with amyloid-beta (AÃÂ²) 
plaques and acetylcholine deficits being central pathological features."
"Selenium (Se) is essential for many nervous system functions 
including memory, cognition and coordination, which has also been linked to a 
variety of neurological disorders, such as epilepsy, Alzheimer's disease (AD) 
and Parkinson's disease (PD).",Alzheimer's disease,epilepsy,ambiguous,Alzheimer's disease,epilepsy,"Selenium (Se) is essential for many nervous system functions 
including memory, cognition and coordination, which has also been linked to a 
variety of neurological disorders, such as [E2] epilepsy [/E2], [E1] Alzheimer's disease [/E1] (AD) 
and Parkinson's disease (PD)."
"Selenium (Se) is essential for many nervous system functions 
including memory, cognition and coordination, which has also been linked to a 
variety of neurological disorders, such as epilepsy, Alzheimer's disease (AD) 
and Parkinson's disease (PD).",Alzheimer's disease,parkinson's disease,ambiguous,Alzheimer's disease,Parkinson's disease,"Selenium (Se) is essential for many nervous system functions 
including memory, cognition and coordination, which has also been linked to a 
variety of neurological disorders, such as epilepsy, [E1] Alzheimer's disease [/E1] (AD) 
and [E2] Parkinson's disease [/E2] (PD)."
"Selenium (Se) is essential for many nervous system functions 
including memory, cognition and coordination, which has also been linked to a 
variety of neurological disorders, such as epilepsy, Alzheimer's disease (AD) 
and Parkinson's disease (PD).",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"Selenium (Se) is essential for many nervous system functions 
including memory, cognition and coordination, which has also been linked to a 
variety of neurological disorders, such as epilepsy, [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) 
and Parkinson's disease (PD)."
"Selenium (Se) is essential for many nervous system functions 
including memory, cognition and coordination, which has also been linked to a 
variety of neurological disorders, such as epilepsy, Alzheimer's disease (AD) 
and Parkinson's disease (PD).",Alzheimer's disease,pd,ambiguous,Alzheimer's disease,PD,"Selenium (Se) is essential for many nervous system functions 
including memory, cognition and coordination, which has also been linked to a 
variety of neurological disorders, such as epilepsy, [E1] Alzheimer's disease [/E1] (AD) 
and Parkinson's disease ([E2] PD [/E2])."
"Selenium (Se) is essential for many nervous system functions 
including memory, cognition and coordination, which has also been linked to a 
variety of neurological disorders, such as epilepsy, Alzheimer's disease (AD) 
and Parkinson's disease (PD).",Alzheimer's disease,neurological disorders,associated_with,Alzheimer's disease,neurological disorders,"Selenium (Se) is essential for many nervous system functions 
including memory, cognition and coordination, which has also been linked to a 
variety of [E2] neurological disorders [/E2], such as epilepsy, [E1] Alzheimer's disease [/E1] (AD) 
and Parkinson's disease (PD)."
"Alzheimer's disease and insomnia: a bibliometric study and visualization 
analysis.",Alzheimer's disease,insomnia,ambiguous,Alzheimer's disease,insomnia,"[E1] Alzheimer's disease [/E1] and [E2] insomnia [/E2]: a bibliometric study and visualization 
analysis."
"Alzheimer's disease (AD) is the fastest-growing neurodegenerative 
disorder globally, with patient numbers expected to rise to 130 million by 2050.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"[E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) is the fastest-growing neurodegenerative 
disorder globally, with patient numbers expected to rise to 130 million by 2050."
"OBJECTIVE: To conduct a visual analysis of the relationship between Alzheimer's 
disease and insomnia using CiteSpace.",Alzheimer's disease,insomnia,ambiguous,"Alzheimer's 
disease and",insomnia,"OBJECTIVE: To conduct a visual analysis of the relationship between [E1] Alzheimer's 
disease and [/E1] [E2] insomnia [/E2] using CiteSpace."
"Literature on ""insomnia"" and ""Alzheimer's disease"" published between 
January 1, 2000, and October 31, 2024, was retrieved from the Web of Science 
Core Collection.",Alzheimer's disease,insomnia,ambiguous,"Alzheimer's disease"" published between 
January 1, 2000, and October 31, 2024, was retrieved from the Web of Science 
Core Collection",insomnia,"Literature on ""[E2] insomnia [/E2]"" and ""[E1] Alzheimer's disease"" published between 
January 1, 2000, and October 31, 2024, was retrieved from the Web of Science 
Core Collection [/E1]."
"White matter hyperintensities (WMHs) are strongly linked to 
cardiovascular risk factors and other health conditions such as Alzheimer's 
disease.",Alzheimer's disease,white matter hyperintensities,associated_with,"Alzheimer's 
disease",White matter hyperintensities,"[E2] White matter hyperintensities [/E2] (WMHs) are strongly linked to 
cardiovascular risk factors and other health conditions such as [E1] Alzheimer's 
disease [/E1]."
"White matter hyperintensities (WMHs) are strongly linked to 
cardiovascular risk factors and other health conditions such as Alzheimer's 
disease.",Alzheimer's disease,wmhs,associated_with,"Alzheimer's 
disease",WMHs,"White matter hyperintensities ([E2] WMHs [/E2]) are strongly linked to 
cardiovascular risk factors and other health conditions such as [E1] Alzheimer's 
disease [/E1]."
"Optimal IR preserves youthful immune profiles at any age, enhances 
vaccine responses, and reduces burdens of cardiovascular disease, Alzheimer's, 
and serious infections.",Alzheimer's disease,infections,ambiguous,Alzheimer,infections,"Optimal IR preserves youthful immune profiles at any age, enhances 
vaccine responses, and reduces burdens of cardiovascular disease, [E1] Alzheimer [/E1]'s, 
and serious [E2] infections [/E2]."
"Optimal IR preserves youthful immune profiles at any age, enhances 
vaccine responses, and reduces burdens of cardiovascular disease, Alzheimer's, 
and serious infections.",Alzheimer's disease,cardiovascular disease,ambiguous,Alzheimer,cardiovascular disease,"Optimal IR preserves youthful immune profiles at any age, enhances 
vaccine responses, and reduces burdens of [E2] cardiovascular disease [/E2], [E1] Alzheimer [/E1]'s, 
and serious infections."
"Alzheimer's disease (AD) is a progressive neurodegenerative disorder that 
affects more than 50 million people worldwide.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"[E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) is a progressive neurodegenerative disorder that 
affects more than 50 million people worldwide."
"Alzheimer's disease (AD) is a progressive neurodegenerative disorder that 
affects more than 50 million people worldwide.",Alzheimer's disease,neurodegenerative disorder,associated_with,Alzheimer's disease,neurodegenerative disorder,"[E1] Alzheimer's disease [/E1] (AD) is a progressive [E2] neurodegenerative disorder [/E2] that 
affects more than 50 million people worldwide."
"Alzheimer's disease (AD) is a prominent neurodegenerative ailment 
characterized by the constraints of conventional therapies stemming from 
insufficient medication transport to the brain.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"[E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) is a prominent neurodegenerative ailment 
characterized by the constraints of conventional therapies stemming from 
insufficient medication transport to the brain."
"Alzheimer's disease (AD) is a prominent neurodegenerative ailment 
characterized by the constraints of conventional therapies stemming from 
insufficient medication transport to the brain.",Alzheimer's disease,neurodegenerative ailment,associated_with,Alzheimer's disease,neurodegenerative ailment,"[E1] Alzheimer's disease [/E1] (AD) is a prominent [E2] neurodegenerative ailment [/E2] 
characterized by the constraints of conventional therapies stemming from 
insufficient medication transport to the brain."
"While it protects the brain from toxins and 
pathogens, it also restricts the delivery of therapeutic agents, posing a 
significant challenge in treating CNS disorders such as Alzheimer's disease, 
Parkinson's disease, and glioblastoma.",Alzheimer's disease,parkinson's disease,ambiguous,Alzheimer's disease,Parkinson's disease,"While it protects the brain from toxins and 
pathogens, it also restricts the delivery of therapeutic agents, posing a 
significant challenge in treating CNS disorders such as [E1] Alzheimer's disease [/E1], 
[E2] Parkinson's disease [/E2], and glioblastoma."
"While it protects the brain from toxins and 
pathogens, it also restricts the delivery of therapeutic agents, posing a 
significant challenge in treating CNS disorders such as Alzheimer's disease, 
Parkinson's disease, and glioblastoma.",Alzheimer's disease,glioblastoma,ambiguous,Alzheimer's disease,glioblastoma,"While it protects the brain from toxins and 
pathogens, it also restricts the delivery of therapeutic agents, posing a 
significant challenge in treating CNS disorders such as [E1] Alzheimer's disease [/E1], 
Parkinson's disease, and [E2] glioblastoma [/E2]."
"Acetylcholinesterase (AChE) is the enzyme targeted by drugs used for the 
symptomatic treatment of cognitive decline associated with Alzheimer's disease.",Alzheimer's disease,cognitive decline,associated_with,Alzheimer's disease,cognitive decline,"Acetylcholinesterase (AChE) is the enzyme targeted by drugs used for the 
symptomatic treatment of [E2] cognitive decline [/E2] associated with [E1] Alzheimer's disease [/E1]."
"Cognitive resilience (CR) contributes to the variability in risk for developing 
and progressing in Alzheimer's disease (AD) among individuals.",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"Cognitive resilience (CR) contributes to the variability in risk for developing 
and progressing in [E1] Alzheimer's disease [/E1] ([E2] AD [/E2]) among individuals."
"Furthermore, we developed a 
Methylation-based Resilience Score (MRS) that successfully predicted future 
cognitive decline in an external dataset from the Alzheimer's Disease 
Neuroimaging Initiative (ADNI), even after accounting for age, sex, APOE ÃÂµ4, 
years of education, baseline diagnosis, and baseline MMSE score.",Alzheimer's disease,cognitive decline,associated_with,"Alzheimer's Disease 
Neuroimaging Initiative (ADNI), even after accounting for age, sex, APOE ÃÂµ4",cognitive decline,"Furthermore, we developed a 
Methylation-based Resilience Score (MRS) that successfully predicted future 
[E2] cognitive decline [/E2] in an external dataset from the [E1] Alzheimer's Disease 
Neuroimaging Initiative (ADNI), even after accounting for age, sex, APOE ÃÂµ4 [/E1], 
years of education, baseline diagnosis, and baseline MMSE score."
"doi: 10.1186/s13195-025-01730-w.

Correction: Investigating the AÃÂ² and tau pathology in autosomal dominant 
Alzheimer's disease: insights from hybrid PET/MRI and network mapping.",Alzheimer's disease,autosomal dominant,associated_with,Alzheimer's disease,autosomal dominant,"doi: 10.1186/s13195-025-01730-w.

Correction: Investigating the AÃÂ² and tau pathology in [E2] autosomal dominant [/E2] 
[E1] Alzheimer's disease [/E1]: insights from hybrid PET/MRI and network mapping."
"Author information:
(1)Huffington Center on Aging, Baylor College of Medicine, One Baylor Plaza, 
Houston, TX, 77030, USA.
(2)Department of Molecular and Human Genetics, Baylor College of Medicine, 
Houston, TX, USA.
(3)Department of Entomology and Nematology and UC Davis Comprehensive Cancer 
Center, University of California, Davis, CA, USA.
(4)Helen and Robert Appel Alzheimer's Disease Research Institute, Weill Cornell 
Medicine, New York, NY, USA.
(5)Huffington Center on Aging, Baylor College of Medicine, One Baylor Plaza, 
Houston, TX, 77030, USA.",Alzheimer's disease,uc,ambiguous,"Alzheimer's Disease Research Institute, Weill Cornell 
Medicine, New York, NY",UC,"Author information:
(1)Huffington Center on Aging, Baylor College of Medicine, One Baylor Plaza, 
Houston, TX, 77030, USA.
(2)Department of Molecular and Human Genetics, Baylor College of Medicine, 
Houston, TX, USA.
(3)Department of Entomology and Nematology and [E2] UC [/E2] Davis Comprehensive Cancer 
Center, University of California, Davis, CA, USA.
(4)Helen and Robert Appel [E1] Alzheimer's Disease Research Institute, Weill Cornell 
Medicine, New York, NY [/E1], USA.
(5)Huffington Center on Aging, Baylor College of Medicine, One Baylor Plaza, 
Houston, TX, 77030, USA."
"Author information:
(1)Huffington Center on Aging, Baylor College of Medicine, One Baylor Plaza, 
Houston, TX, 77030, USA.
(2)Department of Molecular and Human Genetics, Baylor College of Medicine, 
Houston, TX, USA.
(3)Department of Entomology and Nematology and UC Davis Comprehensive Cancer 
Center, University of California, Davis, CA, USA.
(4)Helen and Robert Appel Alzheimer's Disease Research Institute, Weill Cornell 
Medicine, New York, NY, USA.
(5)Huffington Center on Aging, Baylor College of Medicine, One Baylor Plaza, 
Houston, TX, 77030, USA.",Alzheimer's disease,cancer,ambiguous,"Alzheimer's Disease Research Institute, Weill Cornell 
Medicine, New York, NY",Cancer,"Author information:
(1)Huffington Center on Aging, Baylor College of Medicine, One Baylor Plaza, 
Houston, TX, 77030, USA.
(2)Department of Molecular and Human Genetics, Baylor College of Medicine, 
Houston, TX, USA.
(3)Department of Entomology and Nematology and UC Davis Comprehensive [E2] Cancer [/E2] 
Center, University of California, Davis, CA, USA.
(4)Helen and Robert Appel [E1] Alzheimer's Disease Research Institute, Weill Cornell 
Medicine, New York, NY [/E1], USA.
(5)Huffington Center on Aging, Baylor College of Medicine, One Baylor Plaza, 
Houston, TX, 77030, USA."
"Inhibition of sEH has been shown to stabilize the EETs and reduce 
neuroinflammation in AÃÂ² mouse models of Alzheimer's disease (AD).",Alzheimer's disease,ad,equivalent,Alzheimer's disease,AD,"Inhibition of sEH has been shown to stabilize the EETs and reduce 
neuroinflammation in AÃÂ² mouse models of [E1] Alzheimer's disease [/E1] ([E2] AD [/E2])."
"Inhibition of sEH has been shown to stabilize the EETs and reduce 
neuroinflammation in AÃÂ² mouse models of Alzheimer's disease (AD).",Alzheimer's disease,neuroinflammation,associated_with,Alzheimer's disease,neuroinflammation,"Inhibition of sEH has been shown to stabilize the EETs and reduce 
[E2] neuroinflammation [/E2] in AÃÂ² mouse models of [E1] Alzheimer's disease [/E1] (AD)."
